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ABSTRACT
Proteases from the Ovarian Tumor domain (OTU) superfamily of
deubiquitinating enzymes (DUBs) are expressed by a range of RNA viruses. Viral
OTUs (vOTUs) are found in nairoviruses such as Crimean Congo Hemorrhagic Fever
virus (CCHFV), Nairobi sheep disease virus (NSDV), the Erve virus (ERVEV), and the
Dugbe virus (DUGV), as well as in the areterivirus Porcine Reproductive and Respiratory
Syndrome virus (PRRSV), among others. vOTUs, which interfere with host innate
immune response through editing of host Ub and Ub-like molecules such as interferon
stimulated gene 15 (ISG15), have been identified as a potential virulence factor through
their role in evading the innate immune response. Study and characterization of vOTUs
involves evaluating their activity and preferences for Ub, ISG15, as well as the variety of
poly-Ub linkages that can form. While previous studies have compared vOTUs among
different viruses, it was not known how vOTUs from differing strains of the same virus
vary. To investigate vOTUs from differing strains of the same virus, vOTUs from two
strains of PRRSV were selected. The vOTU of a highly pathogenic PRRSV strain,
JXwn06, and a strain used in vaccination, MLV, were enzymatically characterized.
Intriguingly, the JXwn06 vOTU displayed a strong preference for K63 linked di-Ub, with
over 40-fold greater activity than the MLV vOTU. Additionally, neither strain showed
significant activity towards ISG15, which is intriguing, as, at one point, it was believed
ii

that deISGylating activity was a property of all vOTUs. In contrast to these PRRS
vOTUs, a strong deISGylating enzyme, the ERVE vOTU, was selected for enzymatic and
structural investigation. ERVE vOTU was found to not only prefer ISG15 over Ub, but
recognized both mouse and human ISG15. In order to gain insight into this ability to
recognize more than one species of ISG15, the X-ray crystal structure of the ERVE
vOTU in complex with the C-terminal domain of mouse ISG15 (CmISG15) was
elucidated to 2.47 Å. This structure not only revealed the structural configuration of the
ERVE vOTU in complex with its substrate, but also provides the first structural
information for mISG15. Key areas of binding were identified upon comparison of the
manner in which ERVE vOTU recognizes the mouse analog of ISG15 with CCHF vOTU
substrate binding. These key regions were explored through site-directed mutagenesis to
determine if mutation at key binding areas would allow CCHF vOTU to more tightly
bind mISG15. Based on CCHF vOTUs apparent lack of recognition of mISG15, special
ISG15 constructs were designed to allow for testing against a panel of ISG15s from
varying species.
In another area of interest, adenylosuccinate lyase (ADSL) was structurally and
enzymatically investigated to build understanding of ADSL deficiency, a rare autosomal
recessive disorder, which causes a defect in purine metabolism resulting in neurological
and physiological symptoms. To better understand the causation of disease due to
the R303C mutation, the wild type (WT) and the R303C mutant of ADSL were
investigated enzymatically and thermodynamically. Additionally, the X-ray structures
of ADSL in its apo form as well as with the R303C mutation were elucidated, providing
insight into ADSL’s cooperativity.
iii

TABLE OF CONTENTS
Abstract ............................................................................................................................... ii	
  
Table of Contents ............................................................................................................... iv	
  
List of Figures .................................................................................................................... vi	
  
List of Tables ...................................................................................................................... ii	
  
Chapter One: The vOTU Domain of Highly-Pathogenic Porcine Reproductive and
Respiratory Syndrome Virus Displays a Differential Substrate Preference ....................... 1	
  
Introduction ............................................................................................................. 1	
  
Experimental Procedures ........................................................................................ 5	
  
Construction of OTU Domains and Porcine proISG15 .............................. 5	
  
Protein Purification ..................................................................................... 5	
  
Fluorescent vOTU Deubiquitination and DeISGylation Assays ................ 6	
  
Gel Shift Assays.......................................................................................... 7	
  
Assay for vOTU Cleavage of Porcine proISG15 by Anti-FLAG® Western
Blotting. ...................................................................................................... 7	
  
Results ..................................................................................................................... 8	
  
Sequence Comparison of PRRSV strain JXwn06 and MLV vOTU
domains ....................................................................................................... 8	
  
Characterization of Strain Specificity ......................................................... 9	
  
Di-Ubiquitin Specificity Divergence ........................................................ 10	
  
Pro-ISG15 Activity ................................................................................... 13	
  
Discussion ............................................................................................................. 14	
  
Chapter Two: Identifying Factors of Species Preference of vOTUs From CCHFV And
ERVEV Towards ISG15 ................................................................................................... 19	
  
Introduction ........................................................................................................... 19	
  
Experimental Procedures ...................................................................................... 20	
  
vOTU and CmISG15 Construct Design ................................................... 20	
  
Expression of vOTUs and ISG15s ............................................................ 22	
  
Purification of vOTUs and mISG15 ......................................................... 23	
  
Crystallization of ERVE vOTU-CmISG15 .............................................. 26	
  
Site Directed Mutagenesis ........................................................................ 28	
  
Fluorescent deISGylation Assay ............................................................... 28	
  
Mouse ISG15 Competition Assay ............................................................ 28	
  
Pro-ISG15 Cleavage Assay....................................................................... 29	
  
Results ................................................................................................................... 29	
  
Species Specificity of CCHF and ERVE vOTU for ISG15...................... 29	
  
X-ray Crystallographic Elucidation of ERVE vOTU-CmISG15 Structure
................................................................................................................... 31	
  
Inhibition of CCHFvOTU by Mutants of CmISG15 ................................ 33	
  
iv

ProISG15 Gel Shift Assay ........................................................................ 34	
  
Discussion ............................................................................................................. 36	
  
Primary Structure Determinant of Substrate Preference ........................... 36	
  
Diversity of ISG15 Recognition ............................................................... 38	
  
Implications for Mouse Model Systems ................................................... 39	
  
Chapter Three: Structural and Biochemical Characterization of Human Adenylosuccinate
Lyase (ADSL) and the R303C ADSL Deficiency Associated Mutation .......................... 41	
  
Introduction ........................................................................................................... 41	
  
Experimental Procedures ...................................................................................... 44	
  
Materials ................................................................................................... 44	
  
Site-directed mutagenesis, Enzyme Expression, and Purification. ........... 45	
  
Static Light Scattering............................................................................... 46	
  
Enzyme Assays and Kinetic Studies ......................................................... 46	
  
Isothermal Titrations Calorimetry (ITC) .................................................. 48	
  
Crystallization of WT and R303C ADSL ................................................. 48	
  
X-ray Structural Determination of ADSL Structures ............................... 49	
  
Modeling of AMP/AICAR and Fumarate Binding in the Active Site ...... 51	
  
Results ................................................................................................................... 51	
  
WT and R303C ADSL Enzyme Kinetics ................................................. 51	
  
Isothermal Titration Calorimetry (ITC) .................................................... 55	
  
X-ray Structural Elucidation of R303C and WT ADSL ........................... 56	
  
Modeling of AMP/AICAR and Fumarate Binding in the Active Site ...... 63	
  
Discussion ............................................................................................................. 64	
  
Origins of ADSL Cooperativity ................................................................ 64	
  
Catalytic Effects of R303C Mutation ....................................................... 67	
  
References ......................................................................................................................... 72	
  
Appendix A ....................................................................................................................... 83	
  
List of Author’s Publications and Patents............................................................. 83	
  

v

LIST OF FIGURES
Figure 1: Sequence alignment of vOTUs
Figure 2: Kinetic data for fluorescence based assay
Figure 3: Cleavage of di- and tri-Ub
Figure 4: ProISG15 gel shift assay
Figure 5: Sequences alignment of ISG15s and of vOTUs
Figure 6: Generating ERVEvOTU-CmISG15 complex
Figure 7: Inhibition of CCHF and ERVE vOTU by h/mISG15
Figure 8: ERVEvOTU-CmISG15 crystal structure
Figure 9: CCHF vOTU mutants inhibition by CmISG15
Figure 10: ProISG15 gel shift assay
Figure 11: Comparison of Ub and ISG15 bound by CCHF vOTU, ERVE
vOTU and DUG vOTU
Figure 12: Sequence alignment of ADSL from various species
Figure 13: Side and top view of WT homo-tetramer
Figure 14: Comparison of ADSL active sites for WT, WT with substrate,
and R303C mutant
Figure 15: Substrate induced α-helices 2, 3 and 4 shift
Figure 16: ADSL-AICAR-fumarate model
Figure 17: Constriction of the ADSL active site upon substrate binding
Figure 18: Proposed mechanism for SAICAR and AICAR plus fumarate
and for SAMP to AMP plus fumarate

vi

9
10
11
13
21
25
30
32
33
35
37
58
59
61
62
64
67
69

LIST OF TABLES
Table 1: Data Collection and Refinement Statistics, Erve-CmISG15
Table 2: Data Collection and Refinement Statistics, ADSL
Table 3: Enzymatic Activities of ADSL with SAMP and SAICAR at 25 C
Table 4: ITC Thermodynamic Parameters of ADSL

ii

27
50
53
55

CHAPTER ONE: THE VOTU DOMAIN OF HIGHLY-PATHOGENIC PORCINE
REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS DISPLAYS A
DIFFERENTIAL SUBSTRATE PREFERENCE
Introduction
Porcine reproductive and respiratory syndrome virus (PRRSV) is a rapidly
evolving virus which emerged as a serious pathogen of swine in the late 1980’s, and has
since become one of the most significant concerns to the global pork industry. These
concerns have only been exacerbated by the emergence in 2006/2007 of highly
pathogenic PRRSV (HP-PRRSV) in China and Southeast Asia (Li et al. 2007, Wu et al.
2009, Guo, Lager, Henningson, et al. 2013). More contemporary PRRSV isolates have
been observed in Southeast Asia that show significant continuing evolution from the
original 2006 isolates, but still retain the highly pathogenic phenotype (Yu et al. 2012,
Guo, Lager, Schlink, et al. 2013). These observations underscore the need to
mechanistically understand what is responsible for the increased virulence of HPPRRSV, which is further complicated by the complex and poorly understood virulence
determinants of the broad and genetically diverse PRRSV strains.
Upon infection with PRRSV, viremia is typically established in 6-12 hours and
virus shedding has been observed for up to 157 days (Wills et al. 1997). It is likely that
the prolonged time to virus clearance is directly related to the immunosuppressive effects
of PRRSV infection. Although the mechanisms through which PRRSV subverts the
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adaptive immune response have been mostly determined (Sang, Rowland, and Blecha
2011, Yoo et al. 2010, Charerntantanakul, Platt, and Roth 2006), the manner in which
some strains of PRRSV initiate a comprehensive campaign against the innate immune
response have not. Specifically, mechanism behind the apparent dysregulation of several
innate immune pathways such as the type I interferon/IRF/NF-κB mediated innate
immune pathways in cultured cells (Sun et al. 2010, Sun, Han, et al. 2012, Fang et al.
2012, Beura et al. 2010, Song, Krell, and Yoo 2010, van Kasteren et al. 2013), have
remained elusive.
PRRSV is a positive-sense, single-stranded RNA virus in the genus Arterivirus of
the family Arteriviridae. Phylogenetic analysis of PRRSV reveals two genetically distinct
genotypes: Type 1/European PRRSV (type strain Lelystad) and Type 2/North American
PRRSV (type strain VR-2332), with the HP-PRRSV isolates belonging to a distinct
subgroup of Type 2. It is important to note, however, that due to a high rate of mutation
and recombination, it is likely that actual genetic diversity of PRRSV continuously surges
ahead of our ability to discover and characterize it (Shi et al. 2010). The PRRSV genome
is 15 to 15.5 kb, and contains at least 10 open reading frames (ORFs), with 12 nonstructural proteins (nsp) (Chand, Trible, and Rowland 2012). Due to the high degree of
variability in nsp2, it remains likely that functional differences exist in nsp2 between
various PRRSV isolates that might have consequences on strain virulence.
PRRSV nsp2 is a large, highly variable protein encoded in the ORF1a region of
the genome as part of a larger polyprotein precursor (Snijder et al. 1995, Han, Wang, and
Faaberg 2006, van Hemert and Snijder 2008). Nsp2 is liberated from this precursor via
cleavage of the nsp1β:nsp2 junction by the nsp1β protease and cleavage of the nsp2:nsp3
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junction by the intrinsic protease activity of nsp2 (den Boon et al. 1995, Snijder et al.
1995, van Hemert and Snijder 2008, Han, Rutherford, and Faaberg 2009). This protease
activity resides within an amino-terminal region of nsp2 containing a papain-like cysteine
protease domain (PLP2) that cleaves at a conserved GG dipeptide between nsp2 and nsp3
(Han et al. 2009, Ziebuhr, Snijder, and Gorbalenya 2000, Mielech et al.). It has also been
shown bioinformatically that this PLP2 domain is part of a larger family of mammalian
proteins known as the ovarian tumor domain (OTU) proteases (Frias-Staheli et al. 2007).
This subgroup of viral OTU domains (vOTU) have been biochemically shown to act as
deubiquitinases (DUB) of varying specificities and activities, capable of interfering with
innate immune responses via dysregulation of ubiquitin (Ub) or ISG15 related protein
signaling (Frias-Staheli et al. 2007, Capodagli et al. 2011, Akutsu et al. 2011, Capodagli
et al. 2013).
Ub is involved in a number of cell signaling pathways through attachment to host
protiens in a variety of linkages of poly-Ub chains. These poly-Ub chains form via an
isopetide bond between the C-terminus of one Ub with either the N-terminus, or one of
seven other lysine residues, of another Ub molecule. Both mono- and polyubiquitination
of host proteins act as key regulatory steps in multiple distinct cell signaling pathways
(Komander, Clague, and Urbe 2009, Kulathu and Komander 2012). One relevant
example of this is the use of K63-linked poly-Ub in the activation of retinoic acidinducible gene I/mitochondrial antiviral signaling protein (RIG-I/MAVS) (Zeng et al.
2010), linear poly-Ub-dependent activation of inhibitors (IκB kinases) of nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) (Tokunaga et al. 2009), and
K48-linked poly-Ub to trigger degradation of IκB and activation of NF-κB signaling
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(Chen et al. 1995, Alkalay et al. 1995). Alternative forms of ubiquitination (K6, K11,
K27, K33) have been implicated in other cellular functions, including lysosome/vesicle
trafficking, DNA damage response, inhibition of protein degradation, mitochondrial
damage/autophagy, endoplasmic reticulum (ER) associated protein degradation, T-cell
activation, and tumor necrosis factor-alpha (TNFα) signaling (Kulathu and Komander
2012). Further, there exist multiple Ub-like proteins, such as interferon (IFN) stimulated
gene 15 (ISG15), for which there are diverse functions and regulatory pathways including
anti-viral host defense (Zhao et al. 2013). It is clear from this diverse and interwoven set
of processes that it is insufficient to simply define a protease as a vOTU or DUB and
subsequently ascertain the global picture of downstream cellular effects.
Herein, we describe detailed biochemical characterization of the vOTU activity of
the PLP2 domain from a HP-PRRSV strain (JXwn06), and contrast that activity to that
from the PLP2 domain of the avirulent modified live virus vaccine strain Ingelvac
PRRS® (MLV). To do this, we utilized purified vOTU domains in an in vitro activity
assay with chemically defined, purified substrates. This system provides significant
advantages to in cellulo and in vivo activity assays, including the ability to directly query
substrate preference and observe simplified reaction kinetics. Further, these assays avoid
complications due to off-target effects or effects on complex cellular pathways which can
make data interpretation problematic. Using this approach, we demonstrate that both the
MLV and JXwn06 vOTU/PLP2 domains showed DUB activity on K48-Ub and K63-Ub
substrates. Interestingly, the PLP2 domain from HP-PRRSV strain JXwn06 displayed
significantly greater activity against K63-Ub substrates than the PLP2 domain of MLV.
This represents the first report of a biochemical activity unique to HP-PRRSV that has
4

potential implications for increased immunosuppression and may contribute to the
increased virulence exhibited by this Asian HP-PRRSV strain.
Experimental Procedures
Construction of OTU Domains and Porcine proISG15
Ingelvac PRRS® nsp2 nucleotides 1342-1986, coding for nsp2 aa 1-215, were
inserted downstream of a 6x histidine tag, codon optimized for expression in E. coli, and
used to synthesize the viral OTU polypeptide (MLV vOTU) (GenScript, Piscataway, NJ).
A JXwn06 vOTU polypeptide representing nsp2 aa 1-215 was produced in a like manner.
The coding sequence for porcine proISG15 (NM_0011286469) was codon optimized for
expression in E. coli, and internal restriction endonuclease recognition sequences were
altered by silent mutagenesis for cloning purposes (Huang et al. 2009). This optimized
gene was synthesized with an amino terminal 3X FLAG-Tag and 10X His-Tag, as well as
NcoI and BamHI sites for cloning purposes at the 5’ and 3’ ends, respectively
(GenScript). This synthetic gene was subcloned into pET26b (EMD Millipore) for
bacterial expression and purification.
Protein Purification
Porcine proISG15 (pproISG15) was purified from E. coli BL21(DE3) cells
harboring the gene for pproISG15 grown at 37 ˚C in 6 L of LB broth containing 100
µg/mL of ampicillin until the optical density at 600 nm reached 0.6. Expression of
pproISG15 was induced by the addition of IPTG to a final concentration of 0.5 mM at 20
˚C overnight. The cells were resuspended in cold Buffer A (50 mM Tris [pH 7.5], 1 mM
EDTA, and 20% (w/v) sucrose), and then centrifuged at 6700 x g for 30 minutes. The
cells were then resuspended in 5 mM MgCl2. The suspension was centrifuged at 6700 x g
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for 30 minutes, and the protein was purified from the supernatant via Ni-NTA affinity,
followed by size-exclusion chromatography on a Superdex75 using Buffer B (200 mM
NaCl, 20 mM HEPES [pH 7.5], 2 mM DTT). The protein was further purified by cation
exchange using a 10/100 MonoS column. The protein was eluted using a gradient from
Buffer C (100 mM NaCl, 50 mM ammonium acetate [pH 4.5]) to Buffer D (1000 mM
NaCl, 50 mM ammonium acetate [pH 4.5]). The vOTU from Crimean Congo
hemorrhagic fever (CCHFV vOTU) was purified as described previously (Capodagli et
al. 2011).
Fluorescent vOTU Deubiquitination and DeISGylation Assays
All assays were performed in duplicate in Buffer E (100 mM NaCl, 50 mM
HEPES [pH 7.5], 0.01 mg/mL bovine serum albumin (BSA), 5 mM DTT) using a
Corning Costar half-volume black 96-well plate with a reaction volume of 50 µL. The
rates of the reactions were observed using an Infinite M1000 series plate reader (Tecan,
Inc.). Specifically, the increase in fluorescence (excitation λ, 360 nm; emission, 460 nm)
of 7-amino-4-methylcourmarin (AMC) upon cleavage from hUb-AMC, hISG15-AMC,
(Boston Biochem, MA) and ZRLRGG-AMC (Bachem) substrates was monitored for
JXwn06 and MLV vOTU (GenScript). To calculate turnover rates for 1 µM hISG15AMC, 1 µM hUb-AMC, and 50 µM ZRLRGG-AMC, 1 µM, 4 nM, and 4 µM of enzyme
were used against hISG15-AMC, hUb-AMC, and ZRLRGG-AMC, respectively.
The turnover rates for poly-Ub fluorescence resonance energy transfer (FRET)
linkage substrates K11, K48, and K63 (Boston Biochem, MA) were determined by
monitoring the increase in fluorescence (excitation λ, 544 nm; emission, 572 nm)
resulting by the separation of a FRET TAMRA/QXL pair. Cleavage of three
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commercially available FRET TAMRA/QXL pair configurations per K48 and K63 polyUb linkage FRET substrates were assessed. Each di-Ub FRET substrate at 1 µM was
evaluated against an enzyme concentration of 500 nM.
Gel Shift Assays
Poly-Ub linked by the different isopeptide bonds (K6, K11, K29, K33, K48, and
K63), as well as the N-terminal peptide bond (linear), were purchased from Boston
Biochem, MA. K27 linked di-Ub was purchased from Ubiquigent. Dimeric-Ub substrates
(10 µM) were incubated with 500 nM JXwn06 or MLV vOTU in reaction Buffer F (100
mM NaCl, 50 mM HEPES [pH 7.5], and 2 mM DTT) at 37 ˚C. Reactions were stopped at
various times over 1 hour by mixing 9 µL of each reaction with 2 × SDS-Tricine sample
buffer and heating at 95 ºC for 5 minutes. Results were visualized on 10 – 20% MiniPROTEAN® Tris-Tricine Precast Gels (Bio-Rad, CA). For vOTU cleavage of trimeric
K48 and K63 linkages, 20 µM of tri-Ub substrates were tested and analyzed in the same
manner as di-Ub.
10 µM hproISG15, (Boston Biochem, MA) was incubated at 37 ˚C with 20 nM
CCHFV vOTU, 14 µM MLV, or 20 µM JXwn06 vOTU. 10 µM pproISG15 was
incubated at 37 ˚C with 20 nM CCHFV vOTUs. ProISG15 gel shift assays were tested
and analyzed in the same manner as di-Ub. The concentrations of MLV and JXwn06
used were the maximum allowable concentration possible for this assay.
Assay for vOTU Cleavage of Porcine proISG15 by Anti-FLAG® Western Blotting.
The pproISG15 cleavage assays were assembled as described above in reaction
buffer F, containing 10 µM pproISG15, and either 100 nM CCHFV vOTU or 1000 nM
PRRSV vOTU domain. Reactions were incubated at 37 ºC, and aliquots were removed at
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time 0, 1, 2, 5, 10, 30, and 60 minutes, as well as at 24 hours. Reaction progress was
halted by addition of the removed aliquots to an equal volume of SDS-PAGE loading
buffer and storage at -20 ºC until electrophoresis.
Timepoint samples for pproISG15 cleavage assays were separated by 10%
Tris-Tricine SDS-PAGE, and resolved proteins were transferred to a PVDF membrane
using the iBlot transfer apparatus (Life Technologies). The membrane was blocked with
3% milk in PBS and immunoblotted with a 1:3000 dilution of mouse α-FLAG®
monoclonal antibody (Sigma-Aldrich; F1804). Proteins were detected using a 1:15000
dilution of peroxidase conjugated goat α-mouse IgG antibody (Zymax, Life
Technologies) and the ECL Plus substrate (Pierce). Immunoblots were visualized using
blue light fluorescence in a G:BOX imager (Syngene).
Results
Sequence Comparison of PRRSV strain JXwn06 and MLV vOTU domains
The vOTU domains of very few strains of PRRSV have been directly examined
for suppression of innate immunity in cell culture. Two such studies utilized SD01-08 (a
Type 1 isolate) (Sun et al. 2010) or VR-2332 (van Kasteren et al. 2012), which both
cause only mild disease in vivo, and neither of which included an assessment of enzyme
kinetics. Another study examined the ability of HP-PRRSV strain 07HBEZ vOTU to
suppress IFN-β induction in vitro (Li et al. 2010). To more precisely examine and
compare vOTU domain enzymatic activity and specificity for PRRSV strains of differing
pathogenicity, the vaccine derivative, Ingelvac PRRS® MLV and HP-PRRSV strain
JXwn06 were chosen for analysis. A vOTU domain alignment of these two PRRSV
strains compared to a related arterivirus (equine arteritis virus; EAV) and CCHFV was
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produced, using the catalytic and zinc-binding residues as alignment signature amino
acids (Fig. 1). The two PRRSV strains display 83.7% identity/84.2% similarity within the
designated vOTU region, while this domain displays ~21% identity between both
PRRSV strains and EAV, and only ~10% identity between PRRSV and CCHFV.

Figure 1: Sequence alignment of vOTUs. Sequence similarity is indicated as non-conserved (white
background, black text), similar (yellow background, black text), conserved (green background, white
text), or all matching (dark green background, orange text). Catalytic residues are boxed in red, and zincbinding residues are boxed in purple. PRRSV sequence numbering is based on the residue number
within nsp2.

Characterization of Strain Specificity
In order to investigate potential functional differences between vOTU domains
from different PRRSV strains, we obtained biochemical data on the activity and
specificity of PRRSV vOTU domains from strains JXwn06 and MLV. Initially,
enzymatic activity was assessed utilizing Ub and ISG15 substrates, as well as a peptide
substrate comprised of the five C-terminal amino acids common to Ub and ISG15,
RLRGG (Fig. 2). By monitoring the release of the aminomethylcoumarin fluorophore
from the C-terminus of these substrates, rate and substrate preference data was obtained.
The vOTU domains originating from JXwn06 and MLV possess a noteworthy ability to
cleave human Ub-AMC (hUb-AMC) conjugates, at 3.67 ± 0.04 and 2.30 ± 0.04 min-1,
respectively. However, when these vOTUs were assessed for activity against human
9

Figure 2: Kinetic data for fluorescence based assay. JXwn06
vOTU data is shown in gray and MLV vOTU data is shown in
white. ISG15-AMC data is shown in the insert for clarity.
Turnover number of substrate is measured as increase in
fluorescence as AMC is cleaved off of the substrate molecule.

ISG15-AMC (hISG15-AMC), the vOTUs of JXwn06 and MLV exhibited activity 2,500
and 320 times less than their activities toward Ub-AMC, respectively. Interestingly,
when assessed using the peptide substrate ZRLRGG-AMC, which is comprised of the
last five conserved amino acids between Ub and ISG15, a large deviation in activity was
observed between the vOTUs from MLV and JXwn06. Specifically, the activity of the
MLV vOTU was 0.40 ± 0.04 min-1, whereas JXwn06 vOTU was only 2.05 ± 0.01 x 10-2
min-1. This result, as well as the dramatic difference between cleavage of Ub-AMC and
hISG15-AMC, suggests a more complex interaction with the protein substrate beyond
simple recognition of peptide sequence.
Di-Ubiquitin Specificity Divergence
In some cases, vOTU domains have been shown to have higher turnover rates for
poly-Ub than for Ub-AMC due to an increase in the number of favorable contacts to
which the enzyme can bind the substrate (Capodagli et al. 2013). Although the activity
for mono-Ub was found to be relatively similar between JXwn06 and MLV vOTUs,
10

differences in rates of cleavage for di-Ub may exist between strains. To more precisely
differentiate the di-Ub specificities of the JXwn06 and MLV vOTU domains, a panel of
varying di-Ub substrates (composed of K6, 11, 27, 29, 33, 48, 63 and linear di-Ub
linkages; Fig. 3a) was screened for activity. Both vOTU domains had an overall trend of

Figure 3: Cleavage of di- and tri- Ub. (a) Cleavage of various di-Ub linkages by JXwn06 and MLV
vOTUs. (b) Kinetic data for FRET based Di-Ub assay. JXwn06 vOTU data is shown in gray and
MLV vOTU data is shown in white. (c) Cleavage of tri-Ub by JXwn06 vOTU and MLV vOTU.
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highest activity towards K63 linked di-Ub, followed, in descending order, by K11, K29,
K6, K27, and K48-linkage, with no detectable activity toward linear linked di-Ub.
Interestingly, while the observed activity was similar for most di-Ub linkages, JXwn06
vOTU was markedly more active toward K63 di-Ub, cleaving nearly all of the substrate
within 10 min, compared to the MLV vOTU, for which a significant proportion of
uncleaved K63 substrate remained after 60 min. In order to quantify the difference in
activity towards di-Ub substrates, cleavage of K11, K48, and K63 di-Ub FRET substrates
was assessed. These results aligned with the di-Ub gel shift assays, with both vOTU
domains displaying low activity towards K48 linked di-Ub, and disparate activities
utilizing K63 linked di-Ub. The activity of the JXwn06 vOTU towards K63 linked di-Ub
was determined to be approximately 40-fold higher than that of MLV vOTU (Fig. 3b).
To assess potential differences in vOTU domain activity on substrates similar to
poly-Ub, activity assays were performed using K48 and K63 linked tri-Ub (Fig. 3c). In
stark contrast to the K48 linked di-Ub substrate, both vOTU domains of MLV and
JXwn06 rapidly cleaved the majority of K48 tri-Ub into di- and mono-Ub within 5 min.
However, consistent with the previous results, the resulting K48 linked di-Ub appeared
refractory to subsequent vOTU cleavage. As in the di-Ub cleavage assay, the K63 linked
tri-Ub substrate was rapidly and completely cleaved to mono-Ub by the JXwn06 vOTU
domain within 10 min. Unlike the surge in activity observed using K48 linked tri-Ub for
the MLV vOTU domain, its cleavage of K63 linked tri-Ub proceeded at the same modest
rate observed for K63 di-Ub.

12

Pro-ISG15 Activity
While Ub is highly conserved among species, ISG15 is more divergent, with
human and porcine ISG15 sharing 67% sequence homology. Nairovirus vOTUs such as
the CCHFV vOTU have previously been demonstrated to possess species specificity for
ISG15 (Capodagli et al. 2013). To determine if the low hISG15-AMC activity observed
for JXwn06 and MLV vOTU domains was also related to species specificity, cleavage of
the pro-form of human (hproISG15) and porcine (pproISG15) were examined, using the
CCHFV vOTU as a control. First, cleavage of hproISG15 was examined. At the low
enzyme concentration of 20 nM, CCHFV vOTU cleaved the hproISG15 at a rate that was
readily observed in the one-hour time trial (Fig. 4a). Since the PRRSV vOTUs exhibited
much lower turnover numbers for hISG15-AMC, the highest allowable concentrations of
MLV and JXwn06 were utilized. However, even at the increased concentrations for MLV
and JXwn06 vOTUs, no cleavage of the hproISG15 was observed for either in the onehour time span (Fig. 4a). When examining cleavage of pproISG15, while CCHFV vOTU
was seen to cleave the pproISG15 at a significantly reduced rate to that of hproISG15, no
cleavage of pproISG15 by JXwn06 and MLV vOTU domains was detected within a onehour time course. It was only after an extended 24-hour incubation that a trace of cleaved
product was observed (Fig. 4a, b).
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Figure 4: ProISG15 gel shift assay. (a) Cleavage of human (h) proISG15 by CCHFV, JXwn06, or
MLV vOTU is shown over a one-hour time course and visualized by coomasie blue staining. (b)
Cleavage of porcine (p) proISG15 by varying concentrations of CCHFV, JXwn06 and MLV vOTUs
are shown over a one hour time course as well as a 24-hour time point. Cleavage products were
visualized by anti-FLAG® western blot of tagged-pproISG15.

Discussion
The identification of a vOTU domain in nsp2 of the arterivirus PRRSV sets it
among a number of viruses containing vOTUs, including nairoviruses, tymoviruses, a
tenuivirus, and other nidoviruses. Recently, vOTUs from nairovirus representatives
CCHFV, Dugbe virus and Erve virus (ERVEV), as well as the tymovirus prototypical
member turnip yellow mosaic virus (TYMV) were probed extensively, and illustrated
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vOTUs from different species can vary greatly in their preference for substrate
(Capodagli et al. 2013). The vOTUs from JXwn06 and MLV follow this trend. Relative
to previously characterized vOTU domains of viruses, JXwn06 and MLV vOTU domains
displayed moderate deubiquitinating activity. The vOTUs previously probed have
deubiquitinating activity which ranges from approximately 0.03 to 27 min-1 (Capodagli et
al. 2013). The PRRSV vOTUs fall into the lower end of this range, with deubiquitinating
activity closest in value to that of ERVEV vOTU, which is considered a poor
deubiquitinating enzyme relative to other nairoviruses (Capodagli et al. 2013). However,
relative to nairovirus counterparts, such as vOTUs from CCHFV and ERVEV, that
clearly possess deISGylating activity, PRRSV vOTUs deISGylating activity is extremely
low. Comparatively, other vOTUs have activity ranging from ERVEV vOTU at the high
end, at 15 min-1, to TYMV vOTU at the low end with activity of only 0.005 min-1. The
PRRSV vOTUs hISG15 activities are near the lower end of these reported vOTU
activities, with similar values to the TYMV vOTU, whose plant host lacks an ISG15
homologue. Upon comparing the proteolytic activity of the PRRSV vOTUs toward the
last five amino acids common to both Ub and ISG15 as measured by cleavage of
ZRLRGG-AMC, a divergence in their comparative activities was found. The activity of
the MLV vOTU is 20 times greater than that of the JXwn06 vOTU and 30% greater than
the highest activity observed in the recent survey of representative vOTU domains
reported by (Capodagli et al. 2013).
Further comparison and analysis of the vOTU domain from the highly pathogenic
JXwn06 strain of PRRSV with the vOTU domain of the less pathogenic North American
MLV strain revealed an intriguing result. The less virulent MLV vOTU maintained a
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better proteolytic activity, as measured by fold change of relative cleavage of ZRLRGGAMC, and the two vOTUs had similar moderate Ub-AMC activity. However, upon
examining the activity of the two strain’s vOTUs towards poly-linked Ub, rather than the
mono-Ub-AMC, a large divergence in their activities was uncovered. The JXwn06 vOTU
exhibited K63 linked Ub activity over 40 times greater than that of MLV, exemplifying
how vOTUs with similar activity against mono-Ub may have divergent activity towards
different di-Ub linkages. Suppression of K63 linked poly-Ub early in infection by
JXwn06 may contribute to the increased disease severity in highly pathogenic PRRSV
infection.
During initial examination of vOTU domains, such as that from CCHFV, it was
theorized that all vOTUs might possess dual deubiquitinating and deISGylating activity.
However, further work demonstrated that some vOTUs likely serve primarily as
deubiquitinases, while others may have a stronger preference for ISGylated substrates
(Capodagli et al. 2013). For PRRSV vOTU domains from Jxwn06 and MLV, both were
found to not only have very low activity against hISG15-AMC, but were unable to
appreciably cleave either pproISG15 or hproISG15. The latter experiment eliminates a
species-specificity effect, as seen in CCHFV vOTU, as the primary driver for the absence
of activity (Fig 4b,c). As a result, the lack of deISGylating activity suggests that PRRSV
core domain may be more suited as a deubiqutinase than a deISGylase. The lack of
deISGylating activity is surprising given that PRRSV nsp2 has been previously suggested
to play a direct role in reducing the amount of ISGylation in cells (Sun et al. 2012). This
may indicate additional protein requirements for cleavage of ISG15 by PRRSV vOTUs.
These additional requirements may come in the form of accessory proteins, or in a
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requirement for a larger domain within the nsp2 protein, as it has previously been
demonstrated that larger proteolytically active domains of nsp2 were required for trans
vs. cis cleavage specificities (Han, Rutherford, and Faaberg 2009). Alternatively, the
observed cleavage of ISG15 modified proteins in cell culture may be due to an upstream
effect of nsp2, rather than a direct effect of vOTU domain activity. Also, the extended
time course inherent in cellular testing, coupled with the observed trace activity of
PRRSV vOTUs for ISGylated substrates, may have permitted the gradual buildup of
deISGylated substrates thereby exaggerating the magnitude of PRRSV vOTU’s
deISGylating activity. This is of particular importance, given the kinetics of the antiviral
response, particularly in the early stages of viral infection.
PRRSV virulence and attenuation have been studied extensively, with most
studies implicating multiple regions of the virus in contributing to virulence, consistent
with the observation that individual PRRSV vaccines appear to have become attenuated
by different mechanisms (Brockmeier et al. 2012, Wang et al. 2008, Kwon et al. 2008,
Storgaard, Oleksiewicz, and Botner 1999, Ni et al. 2013, Nielsen et al. 2001, An et al.
2011, Shi et al. 2013, Ellingson et al. 2010, Yuan et al. 2001, Han et al. 2013, Kim et al.
2010, Song, Krell, and Yoo 2010). Narrowing the focus to the PLP2/vOTU region of
nsp2, previous reports have generally demonstrated deubiquitinating activity of certain
strains, leading to subsequent suppression of innate immune responses in infected cells
(Frias-Staheli et al. 2007, van Kasteren et al. 2012, Sun et al. 2010, Li et al. 2010),
suggesting a mechanistic role in PRRSV virulence. In this report, we have shown that the
core vOTU domain (215 residues), which varies only 17% (amino acid identity) between
different strains of PRRSV, was responsible for marked differences in K63-linked
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deubiquitination, reinforcing the role of the PLP2/vOTU domain in virulence variation
between PRRSV strains. It is important to note that this core domain must function
primarily as a viral protease, placing significant constraints on evolution of secondary
functions. This also underscores the complexities of PRRSV virulence, since MLV and
its parental field isolate (VR-2332) share the identical vOTU domain sequence while
exhibiting differential pathogenicity in swine. Therefore it is crucial to recognize that
while differential vOTU activity may contribute to virulence, it remains one of a
constellation of potential virulence factors. Mechanistically, several critical innate
immune sensors and cellular anti-viral pathways utilize K63 ubiquitination as an essential
activation step, such as RIG-I/MAVS, MDA5, and MITA/STING (Oshiumi et al. 2013,
Jiang et al. 2012, Guo, Lager, Schlink, et al. 2013). Antagonism of these pathways by a
vOTU domain with preference for K63-polyubiquitin could lead to a decrease in type I
interferon production and NF-κB signaling, thereby abrogating or significantly delaying
establishment of the anti-viral state. If K63 preference and increased deubiquitination
activity of the JXwn06 vOTU domain is a shared characteristic of all highly-pathogenic
PRRSV isolates, then it is possible that this unique activity contributes to the increased
virulence of these strains.
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CHAPTER TWO: IDENTIFYING FACTORS OF SPECIES PREFERENCE OF
VOTUS FROM CCHFV AND ERVEV TOWARDS ISG15
Introduction
Nairoviruses are negative-sense single stranded RNA viruses, which infect both
animals and humans. The genus includes 34 known viruses, of which the CrimeanCongo Hemorrhagic Virus (CCHFV), Dugbe Virus (DUGV), and Nairobi sheep virus
(NSDV) have been the most investigated. The Erve nairovirus (ERVEV), which was
isolated from the white-toothed shrew in 1982 in northwest Europe, has been implicated
as a causative agent in human thunderclap headaches. Among nairoviruses, disease
outcomes in humans can range from mild symptoms, such as headaches, as is the case
with the Erve virus, to severe hemorrhaging, high fever and death with CCHFV
(Capodagli et al. 2013).
Intriguingly, while CCHFV is often fatal in humans, it shows no signs of disease
in a large range of infected animals. Likewise, NSDV, which is fatal in sheep, only
causes mild febrile illness in humans. The most recently identified nairovirus, the
Leopards Hill virus (LPHV), causes severe disease in mice (Ishii et al. 2014). It is
currently unknown why severe disease is presented to only a single species infected with
these nairoviruses. One key factor may lay in the ability of a nairovirus to efficiently
circumvent the immune response of certain species. Recently, a potential nairovirus
virulence factor, ovarian tumor domain protease (vOTU) found within the L-segment of
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narioviruses’ genome, was identified. Investigations into vOTU‘s preference for ubiquitin
(Ub) and Ub-like proteins have revealed differing specificities toward different host’s
Ub-like interferon stimulated gene product 15 (ISG15). Specifically, the vOTU from
CCHFV has been shown to be highly specific to human ISG15 (hISG15), while the
vOTU from ERVEV can recognize both mouse and human ISG15. In order to further
understand this behavior, a complex of the ERVE vOTU with the C-terminal domain of
mouse ISG15 (CmISG15) was elucidated to 2.47 Å. Additionally, constructs of ISG15s
of varying species in a designed pro-form were paneled against varying vOTUs to probe
the vOTUs species preferences further.
Experimental Procedures
vOTU and CmISG15 Construct Design
For the ERVE vOTU expression construct, the first 171 amino acids from the Lprotein in ERVEV (GenBank AFH89032.1), and for the NSD vOTU, the first 186 amino
acids from the L-protein in NSDV (GenBank AED88229.1), which both correspond to
the first 169 amino acids of CCHF vOTU (Fig. 5) and include the OTU domain as
described by Dilcher et al. (2012) were utilized. Similarly to the CCHF vOTU construct,
six histidines and a stop codon were added to ERVE vOTU and NSD vOTU constructs to
generate a C-terminal histidine tag. ERVE vOTU was incorporated into pET11a plasmids
using NdeI and BamHI restriction sites, and NSD vOTU was incorporated into pET28a.
Addgene plasmid 12448 harboring mouse ISG15 (mISG15) in pET15b (mISG15pET15b) as described in Kim and Zhang (2005) was obtained from Addgene. Cysteine 78
of mISG15 was mutated to a serine as described in Sorensen et al. (2007). The C-terminal
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Figure 5: Sequence alignment of ISG15s and of vOTUs. (a) The ISG15 from T. belangeri (Northern
tree shrew), H. sapiens (human), O. aries (sheep), M. musculus (mouse) and O. faciatus (jackknife fish)
are shown aligned. The secondary structure of CmISG15 according to Defined Secondary Structure of
Proteins (DSSP) is shown as blue cylinders (helices), blue arrows (beta sheets), and black lines (loops).
(b) ERVE vOTU, NSD vOTU, CCHF vOTU, and DUG vOTU are shown aligned. The secondary
structure of ERVE vOTU according to Defined Secondary Structure of Proteins (DSSP) is shown as tan
cylinders (helices), tan arrows (beta sheets), and black lines (loops). Dashed lines represent regions for
which electron density was not defined in the crystal structure.

domain of mISG15 (CmISG15) was amplified by PCR, and was then sub-cloned into
pTYB2 using NdeI and SmaI restriction enzyme sites (CmISG15-pTYB2). A CmISG15
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construct in pET15b (CmISG15-pET15b) was generated by PCR amplification of the
entire mISG15-pET15b construct except the N-terminal domain, followed by NdeI
digestion and then ligation. Additional constructs of ISG15 from the sheep Ovis aries
(NCBI reference sequence NP_001009735.1), the northern tree shrew, Tupaia belangeri
(GenBank AFH66859.1), and from the jackknife fish, Oplegnathus faciatus (GenBank
BAJ16365.1) were designed with the same C-terminal additional amino acids as the pro
form of human ISG15 (hproISG15) construct, GTEPGGRSGHHHHHH, generating
constructs termed sheep-proISG15, Nshrew-proISG15, and fish-proISG15, respectively.
These constructs were incorporated into pET15b using NdeI and BamHI restriction sites.
The vOTU and ISG15 constructs were introduced into E. coli BL21 (DE3) competent
cells by heat-shock transformation. The mISG15 construct was heat-shock transformed
into BL21 (DE3)-CodonPlus competent cells. The resulting plasmids were then purified,
restriction analyzed, and sequenced to verify the construct. The hproISG15 construct was
purchased from Boston Biochem.
Expression of vOTUs and ISG15s
For vOTU enzymatic studies, E. coli harboring vOTUs from CCHFV, ERVEV,
mISG15-pET15b, CmISG15-pET15b, or a proISG15 construct were grown at 37 ˚C in
LB broth containing 100 µg/mL of ampicillin until the optical density at 600 nm reached
0.6. Expression of the vOTU, mISG15, CmISG15, or proISG15 gene was induced by the
addition of IPTG to a final concentration of 0.8 mM. The culture was further grown for 4
hrs at 37 ˚C and then centrifuged at 6,000xg for 10 minutes. CmISG15-pTYB2 was
grown similarly, but with an induction by the addition of IPTG to a final concentration of
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0.5 mM, grown at 18˚C overnight. Mutants of vOTUs and CmISG15 were grown the
same as their parent strains. Cells were collected and stored at -80 ˚C until use.
Purification of vOTUs and mISG15
All vOTUs were purified according to the previously published protocol
(Capodagli et al. 2011). Purification of mISG15-pET15b was performed by
enzymatically lysing cells resuspending cells in 500 mM NaCl, 50 mM Tris [pH 7.5], and
1 mM Tris (2-carbozyethyl) phosphine hydrochloride [TCEP-HCl] plus lysozyme. The
solution was then sonicated on ice at 50% power on five seconds, off five seconds for 10
minutes total, using a Sonic Dismembrator Ultrasonic Processor (Fisher Scientific).
Insoluble debris was removed by centrifugation at 17,000xg for 45 minutes. The clarified
extract was filtered with a 0.80 µm filter and then poured over 2 mL of Ni-NTA beads.
The beads were washed with 10 mL lysis buffer supplemented with 10 mM imidazole,
and eluted with 10 mL lysis buffer supplemented with 250 mM imidazole. The elution
was then injected on a Superdex75 size-exclusion column and eluted with a buffer
containing 200mM NaCl and 50 mM HEPES [pH 8.0]. All final protein concentrations
were determined by absorbance at 280 nm using calculated extinction coefficients (Gill
and von Hippel 1989).
Purification of CmISG15-pTYB2 was performed by chemically lysing cells by
resuspending cells in CmISG15 lysis buffer (25 mM HEPES pH 6.8, 50 mM sodium
acetate, and 75 mM NaCl), augmented with 0.16% Triton X-100. The solution was then
sonicated on ice at 50% power on five seconds, off five seconds for 10 minutes total.
Insoluble debris was removed by centrifugation at 17,000xg for 45 minutes. The clarified
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extract was filtered with a 0.80 µm filter and then poured over a chitin column preequilibrated with CmISG15 lysis buffer. The column was washed with three column
volumes of CmISG15 lysis buffer, followed by resuspension of the beads in two column
volumes of CmISG15 lysis buffer supplemented with 250 mM sodium 2mercaptoethanesulfonate (MESNA). The resuspension was rocked gently overnight at 4
˚C to allow the MESNA to cleave the CmISG15 protein off of its chitin binding fusion
tag. The chitin bead / protein solution was poured into a XK 26/40 GE column and the
flow-through was collected. The resulting CmISG15 thioester solution was then
concentrated to reduce the volume to 20 mL. Then 480 µL 5 M NaOH and 1.84 g
propargylamine were added to the CmISG15 thioester, which was then incubated
overnight at 4°C to create the suicide substrate, CmISG15-PA. Purified ERVE vOTU
was added directly to the solution containing CmISG15-PA in equi-molar ratios, and was
incubated at room temperature for 4 hours to create the ERVE vOTU-CmISG15
complex. This protocol was adapted from previously described methods (Messick et al.
2008, Wilkinson, Gan-Erdene, and Kolli 2005), and is illustrated in Fig. 6. The complex
was further purified by anion exchange chromatography, eluting from a GE MonoQ
10/100 column using a linear gradient from 50 mM Tris [pH = 7.3] to 50 mM Tris [pH =
7.3], 1 M NaCl, followed by size exclusion chromatography on an AP-1 (Waters) column
packed with Superdex75 resin preequilibrated with 100 mM NaCl, 5 mM Hepes [pH =
7.5], 2 mM DTT.
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Figure 6: Generating ERVEvOTU-CmISG15 complex. (a) Cleavage of CmISG15 from Chitin binding domain fusion protein by
mercaptoethanesulfonate. (b) Derivitization of C-terminus of CmISG15 by propargylamine (PA) to create suicide substrate CmISG15-PA. (c)
Complexation of CmISG15-PA with ERVE vOTU to create covalently bound ERVEvOTU-CmISG15 complex for crystallization

Crystallization of ERVE vOTU-CmISG15
Purified ERVE vOTU-CmISG15 was concentrated to 12.5 mg/mL using Vivaspin
6 10-kDa MWCO concentrators and filtered using a 0.22 µm pore size Costar spin filter,
and screened against a panel of QIAGEN NeXtal Suites using a TTP Labtech Mosquito.
Initial screening resulted in several hits of needle-like crystals, the most viable of which
formed in 6% PEG 6000, 0.1 M citric acid [pH = 4.6]. These were further optimized
utilizing the Additive HT Screen from Hampton Research. Final rod-shaped ERVE
vOTU-CmISG5 crystals were obtained through vapor diffusion using a 500 µL reservoir
with 2 µL hanging drops mixed 1:1 with protein solution and reservoir solution
supplemented with 0.2 µL 3.0 M NDSB-195. The crystal was transferred to a
cryoprotective solution of 30% PEG 6000, 0.1 M citric acid [pH = 4.6], and then flash
cooled in liquid nitrogen. The frozen crystal was mounted under a stream of dry N2 at
100 K. An ERVE vOTU-CmISG15 data set with resolution of 2.47 Å was collected at the
Advanced Photon Source (APS) beamline BM-22 at 1.00 Å with a MAR300hs detector.
X-ray images were indexed, processed, integrated, and scaled using HKL2000
(Otwinowski and Minor 1997). An initial phase solution was elucidated using a
homology model based on the DUB vOTU-Ub structure 4HXD using Phaser. The
structure was refined using iterative cycles of model building and refinement using
COOT and PHENIX, respectively (Emsley and Cowtan 2004, Adams et al. 2010). Water
molecules were added to the 2Fo-Fc density peaks of >1σ using the Find Water COOT
program function. The final model was checked for structural quality using the CCP4
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suite programs Procheck and Sfcheck. The data refinement statistics are shown in Table
1.
Table 1: Data Collection and Refinement Statistics
Erve-CmISG15
Data Collection
Space Group

P 43

Unit Cell Dimensions
a, b, c (Å)

66.0, 66.0, 122.0

α=β=γ (degrees)

90.0, 90.0, 90.0

Resolution (Å)

50.0-2.47

No. Reflections Observed

36,660

No. Unique Reflections

18,742

Rmerge (%)

13.6 (55.9)*

I/σI

11.5 (2.56)*

% Completeness

100.0 (100.0)*

Refinement
Resolution Range

50.0-2.47

No. Reflections in Working Set

17,722

No. Reflections in Test Set

986

Rwork (%)

18.3

Rfree (%)

23.3

Mean B-factor (Å2 )

16.2
2

15.3

Water B-factor (Å )

22.5

Protein B-factor (Å )
2

RMS deviation:
Bond Lengths (Å)

0.009

Bond Angles (degrees)

1.43

Protein / Water Atoms

3829/251

Monomers in Asymmetric Unit

2

* The last resolution shell is shown in parentheses.
a Rmerge=ΣhΣi|Ii(h)−〈I(h)〉|/ΣhΣiIi(h), where Ii(h) is the ith
measurement and 〈I(h)〉 is the weighted mean of all
measurements of I(h).
b Rwork and Rfree=h(|F(h)o|−|F(h)c|)/h|F(h)o| for reflections in
the working and test sets.
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Site Directed Mutagenesis
Mutants of CCHF vOTU were generated using QuikChange site-directed
mutagenesis according to the manufacturer’s protocol (Agilent Technologies, Inc.). The
resulting mutant plasmids were introduced into E. coli XL1-Blue Supercompetent cells
by heat shock transformation and were then propagated, purified for sequence
verification, and transformed into E. coli BL21(DE3) cells for enzyme expression. The
complete coding regions for all mutant enzymes were sequenced by Eton Bioscience, Inc.
Fluorescent deISGylation Assay
All assays were performed in duplicate in 100 mM NaCl, 50 mM HEPES [pH
7.5], 0.01 mg of bovine serum albumin [BSA]/ml, 5 mM dithiothreitol [DTT] using a
Corning Costar half-volume black 96-well plate with a reaction volume of 50 µl. The
rates of the reactions were observed using a CLARIOstar series plate reader (BMG
LABTECH). Specifically, the increase in fluorescence (excitation λ, 360 nm; emission,
460 nm) of 7-amino-4-methylcourmarin (AMC) upon cleavage from human ISG15-AMC
(hISG15-AMC) (Boston Biochem, MA) was monitored for each of the vOTUs. A
calibration curve for AMC was generated by addition of excess vOTU to various
concentrations of Ub-AMC, and the reactions were allowed to run until the fluorescence
signal was no longer increasing with time. The resulting maximum fluorescence values
were plotted to determine the slope and subsequently create a calibration curve.
Mouse ISG15 Competition Assay
The ability of 4 nM vOTU from CCHF vOTU and ERVE vOTU to cleave 2 µM
hISG15-AMC in the presence of unlabeled mISG15 (120 µM) or hISG15 (120 µM) was
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observed by measuring the increased fluorescence of free AMC (excitation λ, 360 nm;
emission, 460 nm) on an Infinite M1000 series plate reader (Tecan). Unlabeled mISG15
was obtained as described above, whereas hISG15 was acquired from a commercial
source (Boston Biochem). All assays were performed in buffer 200 mM NaCl, 50 mM
HEPES [pH 8.0], 0.01 mg of BSA/ml, 5 mM DTT using a Corning Costar half-volume
black 96-well plate with a reaction volume of 50 µl. The ability of 4 nM CCHF vOTU to
cleave 1 µM hISG15-AMC in the presence of mISG15 (700 µM), or CmISG15 (700 µM)
was measured as above using a CLARIOstar series plate reader (BMG LABTECH).
Pro-ISG15 Cleavage Assay
10 µM of purified sheep-proISG15, Nshrew-proISG15, or fish-proISG15, or
hproISG15 (Boston Biochem, MA) were incubated with 20 nM CCHF, ERVE, NSD
vOTU, or SARS PLpro in 100 mM NaCl, 5 mM HEPES [pH 7.5], and 2 mM DTT at 37
˚C. Reactions were stopped at various times over 1 hour by mixing 9 µL of each reaction
with 2 × SDS-Tricine sample buffer and heating at 95 ºC for 5 minutes. Results were
visualized on 10 – 20% Mini-PROTEAN® Tris-Tricine Precast Gels (Bio-Rad, CA).
Results
Species Specificity of CCHF and ERVE vOTU for ISG15
Unlike Ub, which is highly conserved among eukaryotes, ISG15 and its known
homologs contain significant sequence variability, even among mammals. Previously,
studies have suggested that vOTUs may prefer to cleave hISG15 or equivalent homologs
specific to the species they infect(Capodagli et al. 2011). To investigate the effect of
species diversity in ISG15s on vOTUs’ ability to cleave these conjugates, unlabeled
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hISG15 and mISG15 were used as competitive inhibitors against vOTUs from CCHFV
and ERVEV. Predictably, both vOTUs show >90% decreases in their abilities to cleave
hISG15-AMC in the presence of unlabeled hISG15. However, the presence of unlabeled
mISG15 has a divergent effect between the two vOTUs. For CCHF vOTU, mISG15 lacks
appreciable ability to interfere with this vOTU’s cleavage of hISG15-AMC, revealing
that CCHF vOTU substantially prefers hISG15 to mISG15 (Fig. 7). Interestingly, ERVE
vOTU is inhibited by approximately 30% at the same mISG15 concentration, suggesting
that affinity for certain species’ ISG15s, or homologs, may vary among nairovirus
vOTUs.

Figure 7: Inhibition of CCHF and ERVE vOTU by h/mISG15. Unlabeled m/hISG15 were
evaluated as inhibitors of CCHF or ERVE vOTU in the hISG15-AMC assay.
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X-ray Crystallographic Elucidation of ERVE vOTU-CmISG15 Structure
In order to further understand the structural basis for the multi-species recognition
by ERVE vOTU, as well as elucidation of the structural features of CmISG15, a
covalently bound complex of ERVE vOTU and CmISG15 (ERVEvOTU-CmISG15) was
solved to 2.47 Å (Table 1). As has been found for other nairovirus vOTUs, CCHFvOTU
and DUGvOTU, the ERVEvOTU possess similar global folds. It is composed of a core
of seven β-sheets, flanked by seven α-helices, and three 310 helices (Fig 8a). Interestingly,
the ERVEvOTU-CmISG15 structure shared several similarities with the DUGvOTU-Ub
(4HXD) structure reported by Capodagli et al. (2013). Specifically, it possesses the same
shift at the alpha-3 helix seen with DUG vOTU when compared to CCHF vOTU. This
helix is partly situated in a highly conserved amino acid sequence, which is flanked by
more variable regions. In the middle of the α3-helix, where there is a transition from
conserved to variable region, and positioned such that it is interfacing with the substrate
binding interface, is CCHF vOTUs R80, which corresponds to Erve vOTUs I83. The
corresponding ISG15 residues with which R80 and I83 interact are conserved between
human and mouse ISG15. Interestingly, upon examination of vOTUs’ interaction with
their respective ISG15 substrate, the positively charged R80 and hydrophobic I83 each
favorably interact with the conserved ISG15 region (Fig 8d-f). The hISG15 is situated
such that its E132 is interacting with CCHF vOTUs R80, and P132 is shifted away.
Similarly, the mISG15 is shifted such that its P128 is hydrophobically interfacing with
ERVE vOTUs I83, while its E130 is not involved in binding (Fig 8d). This shift is driven
by the variation in the vOTU, not the substrate. Variations in substrates are
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Figure 8: ERVEvOTU-CmISG15 crystal structure. (a) ERVEvOTU-CmISG15 crystal structure
with ERVE vOTU rendered in light orange, and mISG15 in light blue. (b) Comparison of
CCHFvOTU-ChISG15 (PDB entry 3PHX) with ERVEvOTU-CmISG15. ERVEvOTU-CmISG15 is
rendered as in (a), CCHF vOTU is rendered orange, and ChISG15 is blue. Boxed in green is shown in
detail in (d), boxed in red is shown in (e), and boxed in yellow is shown in (f). (d) Comparison of the
α3 helix-binding interface between CCHFvOTU-ChISG15 and EVREvOTU-CmISG15, colored as in
(b). (e) β-sheet / substrate binding interface of CCHF vOTU E128 with hISG15 K90, colored as in (b).
(f) ERVE vOTU R21 H-bonding with CmISG15 backbone through coordinated water molecule, which
is represented as a cyan sphere, while proteins are colored as in (b).

accommodated by the vOTU on the other side of the binding pocket in the β-sheet /
substrate interface. Specifically, CCHF vOTU’s E128, which faces into the binding
pocket, interacts with the hISG15 K90 (Fig. 8e). By comparison, ERVE vOTU’s
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corresponding I131 does not favorably interact with either hISG15 or mISG15 in that
location, and its mISG15 substrate is shifted away from this residue. To compensate, in
another area of the binding pocket, ERVE vOTUs R21 can hydrogen bond with the
carbonyl backbone of mISG15 through a coordinated water molecule, where CCHF
vOTU’s V18 is not favorably interacting with hISG15 (Fig. 8f).
Inhibition of CCHFvOTU by Mutants of CmISG15
Upon examination of ERVEvOTU-CmISG15 overlaid with CCHFvOTUChISG15, key areas were identified as possible recognition sites for ERVEvOTU’s
accommodation of both mISG15 and hISG15. While CCHF vOTU mutants V18R and
E128I both significantly decreased in activity towards hISG15-AMC by approximately
50 and 60%, respectively, neither mutation made appreciable gains in recognition of
CmISG15 by CCHF vOTU (Fig. 9).

Figure 9: CCHF vOTU mutants inhibition by CmISG15.
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ProISG15 Gel Shift Assay
In order to further explore the degree of species preference of varying nairovirus
vOTUs, special constructs of ISG15 from human, sheep, northern tree shrew, and
jackknife fish (hproISG15, sheep-proISG15, Nshrew-proISG15, and fish-proISG15,
respectively) were designed with additional amino acids on the C-terminus. These amino
acids are the sequence found on the pro-form on hISG15, plus a His-tag. By eliminating
variation in this extension of the substrate, variation in the vOTUs’ preference for these
ISG15s could be investigated. CCHF vOTU readily cleaved the hproISG15 to completion
within about 10 minutes (Fig. 10). Interestingly, it also cleaved the sheep-proISG15 and
Nshrew-proISG15 rapidly, and after an extended time, 30-60 minutes, had cleaved a
small amount of fish-proISG15. ERVE vOTU completely cleaved the hproISG15 within
about 60 minutes, had about equal cleavage for the sheep-proISG15, a trace of activity
toward fish-proISG15, but possessed zero activity toward the Nshrew-proISG15, even
after 60 minutes. NSD vOTU cleaved both hproISG15 and NShrew-proISG15
completely after 30 minutes, and showed zero activity toward fish-proISG15.
Interestingly, it rapidly cleaved the sheep-proISG15 within about 5 minutes. In contrast
to the vOTUs, SARS PLpro was also paneled against the pro-ISG15 constructs. SARS
PLpro exhibited moderate cleavage of hproISG15, leaving a trace amount uncleaved after
60 minutes, cleaved the sheep- and Nshrew-proISG15s within about 10 minutes, and was
the DUB which exhibited the most activity toward fish-proISG15, cleaving about 40%
within 60 minutes (Fig. 10). While SARS PLpro was more robust than the vOTUs
towards the fish-proISG15, it still displayed preference for human, N. shrew, and sheep.
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Figure 10: ProISG15 Gel Shift Assay. CCHF, ERVE, or NSD vOTU, plus SARS
PLpro were evaluated for cleavage of human, sheep, N.shrew, and fish proISG15.
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Discussion
Primary Structure Determinant of Substrate Preference
In Capodagli et al. (2013), it was determined that the primary structure of the
CCHF and DUG vOTUs were key factors in substrate preference, and that global
secondary and tertiary structural features were mainly conserved, with the minor
exception of a shift of the α3-helix. In a similar manner, ERVE vOTU possesses
conserved global folds of other nairovirus vOTUs, with a shift in the α3-helix similar to
DUG vOTU. Ultimately, while the primary structure appears to be the driving force in
determining substrate recognition, it results in slight shifting of the substrate within the
binding pocket. This shift appears to accommodate varying substrates by balancing
favorable contacts in different area of the binding pocket, specifically balancing favorable
amino acid interactions on the binding interface between the β-sheet and substrate
interface on the opposite side of the binding pocket as the α3-helix (Fig. 11). These slight
adjustments of the substrate within the binding pocket allow the vOTUs to possess their
dual activities towards varying substrates. While others have identified specific amino
acid residues which can modulate the activity of CCHF or DUG vOTU toward Ub or
ISG15 (James et al. 2011, Akutsu et al. 2011, Capodagli et al. 2013), there do not appear
to be global control switches for Ub and ISG15 activity, but rather a collection of
variations to the binding interfaces which have individually evolved for each vOTU.
Furthermore, this shifting of substrate within the binding pocket may ultimately be what
allows vOTUs to appear to possess activity towards substrates to which they could not
have had evolutionary pressure to develop activity towards, as is the case with Turnip
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Yellow Mosaic Virus (TYMV) as shown by Capodagli et al. (2013), which can be
shown, at sufficiently high concentrations, to cleave hISG15-AMC, which is not known
to exist in plants. Along a similar line, CCHF vOTUs lack of recognition towards
mISG15 creates inherent problems for any mouse model systems for study of CCHFV.
Under biologically relevant conditions, CCHF vOTU does not possess sufficient
recognition of mISG15 to interfere with its role in viral immune response in mice.

Figure 11: Comparison of Ub and ISG15 bound by CCHF vOTU, ERVE vOTU and DUG vOTU.
the vOTUs from CCHFvOTU-Ub (PDB ID: 3PRP), DUGvOTU-Ub (PDB ID: 4HXD), CCHFvOTUChISG15 (PDB ID: 3PHX), and ERVEvOTU-CmISG15 were structurally aligned using SSM
Superpose, and the resulting overlay of their respective substrates is shown. Ub bound to CCHF vOTU
is shown green, Ub bound to DUG vOTU is red, ChISG15 bound to CCHF vOTU is cyan, and
CmISG15 bound to ERVE vOTU is blue.
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Diversity of ISG15 Recognition
Based on the inability of mISG15 to inhibit CCHF vOTU, it was hypothesized
that CCHF vOTU was a more selective vOTU than ERVE vOTU, with a high specificity
towards hISG15. The proISG15 gel shift assay revealed that CCHF vOTU can, in fact,
cleave a variety of species’ ISG15s. CCHF vOTU’s high activity towards hISG15 and
NSDV’s strong preference and activity toward sheep ISG15 are in line with the role of
the vOTU as a virulence factor through targeting ISG15 in species resulting in a high
mortality rate. However, while a high activity toward ISG15 may be an indicator for
virulence, it alone cannot explain why CCHFV is only found to be lethal in humans,
when it also readily cleaves sheep and shrew ISG15. While the activity of the vOTU has
been identified as one potential virulence factor, it is apparent that there are other factors,
which have yet to be identified, that may work in concert with the robust vOTU
deISGylation to result in high mortality for specific species.
Intriguingly, ERVE vOTU, which was inhibited by mISG15, and also readily
cleaves sheep and human proISG15s, had no measurable activity towards the Northern
shrew’s ISG15. While ERVEV was isolated from the white-toothed shrew, this may
represent another possible outcome of mutations that favor one substrate, such as Ub, or
to become specific to one species’ substrate, such as ISG15, when balancing competing
factors affecting the vOTUs substrates preferences, and still maintaining necessary
proteolytic activity for viral polypeptide processing. Favoring one role over another may
cause a loss in activity for one and gains for another. Alternatively, in the possible
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absence of a strong IFN response to infection by ERVEV in shrew, there may not be
pressure for the ERVEV to develop activity toward the shrew’s ISG15.
Including SARS PLpro in the panel of DUBs cleaving proISG15 constructs
provides insight into the behavior of a different class of DUB. SARS PLpro has been
shown to be a di-distributive DUB, preferentially cleaving K48 linked poly-UB, leaving
behind mono-Ub on substrates (Ratia et al. 2014). While it cleaved all of the ISG15s
paneled, it may be less driven by primary structure, as is seen with the vOTUs, and more
by tertiary structural folds. It was seen by Ratia et al. (2014) that its specificity toward
K48 poly-Ub over K63 poly-Ub was driven by a secondary binding site which
accommodated K48 over the linear, K63 linkage, with the more condensed, bent structure
of K48 nested into both its proximal and distal binding sites. It may be that the flexibility
of the middle, hinge region of ISG15s allow them to conform to fit in the binding site of
SARS PLpro. While only the C-terminal lobe of ISG15 is involved in binding to vOTU
active sites, based on the manner in which K48 Di-Ub is proposed to fit into the SARS
PLpro active site, it is likely that both lobes of ISG15 are involved in binding to SARS
PLpro.
Implications for Mouse Model Systems
The elucidation of the x-ray structure of CmISG15 not only provides the first
structural information for mISG15, but opens the door for further developing methods for
potentially utilizing mouse model systems for study of viruses which express vOTUs,
such as CCHFV. Current studies have demonstrated how to turn on and off specific
substrate activities through mutation of select amino acids. Based on the findings that the
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primary structure is key in dictating substrate selectivity, it is plausible that a hybrid
vOTU could be developed which possesses robust activity towards mISG15, which could
be investigated for a mouse model system for the development of therapeutics for
CCHFV.
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CHAPTER THREE: STRUCTURAL AND BIOCHEMICAL
CHARACTERIZATION OF HUMAN ADENYLOSUCCINATE LYASE (ADSL)
AND THE R303C ADSL DEFICIENCY ASSOCIATED MUTATION
Introduction
Adenylosuccinate lyase (ADSL) deficiency is a rare autosomal recessive disorder
characterized by serious neurological and physiological symptoms such as psychomotor
retardation (PMR), expression of autistic features, structural brain abnormalities, axial
hypotonia, seizures, peripheral hypotonicity, ataxia, muscle wasting, growth retardation
and strabismus (Spiegel, Colman, and Patterson 2006, Mouchegh et al. 2007, Gitiaux et
al. 2009). More than 60 cases of ADSL deficiency have been reported worldwide, but it
is widely considered to be underdiagnosed (Köhler et al. 1999, Jurecka et al. 2008,
Ciardo, Salerno, and Curatolo 2001). ADSL deficiency is clinically diagnosed by
elevated levels of succinylaminoimidazolecarboxamide riboside (SAICAr) and
succinyladenosine (S-Ado) in urine, plasma, and cerebrospinal fluid (Georges and Berghe
1984). Three distinct phenotypic groups have been established: 1) Neonatal; 2) Type I; 3)
Type II. The neonatal form results in fatal neonatal encephalopathy and has a SAdo:SAICAr ratio of <1. Type I patients experience early onset, severe PMR, and have a
ratio of ~1. Type II patients experience later onset with mild PMR, and have a ratio of 2–
4 (Van den Bergh, Vincent, Jaeken, and Berghe 1993). There are three main hypotheses
that describe the difference in ratio: 1) nonparallel reduction in the enzyme’s activity on
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its substrates; 2) differential dephosphorylation or transport of the substrates out of the
cells (Van den Bergh, Vincent, Jaeken, and Berghe 1993, Hürlimann et al. 2011), and 3)
inability of ADSL mutant protein to form an active purinosome, which is formed when
purine synthesis is required and is needed for appropriate channeling of
succinylaminoimidazolecarboxamide ribonucleotide (SAICAR) through the de novo
purine synthesis pathway (Baresova et al. 2012). ADSL carries out two non-sequential
steps of de novo AMP synthesis, the conversion of SAICAR and succinyladenosine
monophosphate (SAMP) into aminoimidazolecarboxamide ribotide (AICAR) and
adenosine monophosphate (AMP), respectively, with the concomitant release of fumarate
in each case (Lundy et al. 2010). The conversion of SAMP to AMP is also part of the
purine nucleotide cycle. So far, all mutations, with one exception, result in a proportional
loss of enzyme activity with the two substrates. The ADSL carrying the R303C mutation
has been observed as a homozygous mutation in two unrelated patients. It is a type II
mutation and results in the mildest observed form of ADSL deficiency. Interestingly, this
mutation shows a more severe loss in activity with SAMP than with SAICAR, although
the extent of disproportionality varies from study to study, perhaps reflecting differences
in how the enzyme assays were carried out. Some investigators were unable to detect
activity with SAMP in extracts from fibroblasts (Race et al. 2000), while others found 3%
of normal activity (Van den Bergh, Vincent, Jaeken, and Berghe 1993). In other cases
using different recombinant ADSL constructs, 7% and 18 % of wild-type (WT) activity
was observed with SAMP and 44% with SAICAR (Race et al. 2000, Zikánová et al.
2010). The reason for the non-parallel loss of activity is not yet understood, nor is the
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reason why this mutation leads to such a mild phenotype. Hypotheses include the
possibility that different amino acids in the active site bind the two substrates, that
cysteine is not able to interact well with SAMP, or that there are alterations in the
stability of the active site cleft (Race et al. 2000, Zikánová et al. 2010). Crystal structures
of the bacterial ADSL and other studies have provided insight into the active site and the
catalytic mechanism; however these studies predominately use bacterial ADSL from
organisms such as Thermotoga maritima or Escherichia coli (Toth et al. 2000, Tsai et al.
2007). T. maritima and Homo sapiens have a sequence identity of 25% and similarity of
57%. E. coli and H. sapiens have a sequence identity of 23% and a similarity of 57%
(Fig. 12). ADSL was found in these bacterial species to function in the pathway as a
homotetramer. Interestingly, three monomers contribute to each of the four active sites in
the tetramer (Sivendran and Colman 2008, Brosius and Colman 2002). The use of
Bacillus subtilis ADSL in particular as a model to study properties of mutant enzymes in
some cases involved modification of additional amino acid residues in the B. subtilis
ADSL to more closely resemble human ADSL (Sivendran et al. 2004, Palenchar and
Colman 2003). However, attempts to make use of a B. subtilis model system to replicate
the R303C phenomenon have proven difficult because B. subtilis and H. sapiens only
have a sequence identity of 30% and a similarity of 63%. Specifically, the sequence
diversity of B. subtilis and H. sapiens results in multiple alterations within the active site
including, but not limited to, an asparagine residue in place of the corresponding R303 in
human ADSL, as well as an arginine residue in place of human corresponding T354. Not
surprisingly, the removal of B. subtilis’s asparagines at the corresponding human ADSL
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R303 position for cysteine did not generate a disproportional reduction in catalytic ability
(Palenchar and Colman 2003, Sivendran et al. 2004). This observation as well as others
suggest that the study of the bacterial enzyme, while initially useful for understanding
some of the basic features of ADSL, such as its tetrameric nature and participation of
three subunits in forming each active site, may not be as useful for understanding the
effects of various disease causing mutations on the human enzyme. Only limited
structural information exists of human ADSL active site in the unpublished SAMP bound
and S-AMP/AMP-fumarate bound PDB deposited entries (2J91, 2VD6). Current studies
on disease-associated mutations of human ADSL have focused on correlation of substrate
activity with clinical phenotypes, thermal stability of ADSL, activity of hybrid WT
ADSL and mutants, and global changes in structure (Zikánová et al. 2010, Ariyananda et
al. 2011, Ariyananda et al. 2009, Race et al. 2000, Kmoch et al. 2000). They have not
investigated local structural changes or binding properties to the products within the
ADSL active site. In this study, we present structural and biochemical characterization
data of WT and mutant R303C ADSL by enzyme kinetics, product binding by isothermal
titration calorimetry (ITC), and X-ray crystallography to reveal the effects of the R303C
mutation that results in nonparallel reduction in enzyme activity.
Experimental Procedures
Materials
Chemicals, biochemicals, buffers, and solvents were purchased from SigmaAldrich Chemical Co. (St. Louis, MO), Fisher Scientific Inc. (Pittsburgh, PA), Fluka
Chemical Corp. (Milwaukee, WI), or EM Science (Cincinnati, OH). The Centricon and
44

Ultrafree centrifugal filter devices were obtained from Millipore Co. (Billerica, MA).
Nickel-nitrilotriacetic acid-agarose, a QIAspin kit, and high throughput crystal condition
screens were purchased from QIAGEN. Additive HT Screen was purchased from
Hampton Research. QuikChange site directed mutagenesis kit was purchased from
Stratagene. SAICAR was prepared enzymatically from AICAR purchased from SigmaAldrich Chemical Co. as described by Zikánová et al. (2005). Enzymes and reagents used
for molecular biology procedures were obtained from New England Biolabs, Inc.
(Ipswich, MA).
Site-directed mutagenesis, Enzyme Expression, and Purification.
The initial WT ADSL construct was obtained from Dr. Roberta F. Colman,
Department of Chemistry and Biochemistry, University of Delaware, Newark, DE. The
full description of the initial WT ADSL construct is described in Lee and Colman (2007).
In short, the full length human ADSL gene (1-484 residues) was constructed in pET-14b
vector containing a 5’end NdeI restriction site and a 3’-end BlpI restriction site and a
thrombin cleavable N-terminal histidine tag. In order to overexpress the human enzyme
in E. coli, the vector was transformed into E. coli Rosetta 2(DE3)pLysS. The WT and
R303C ADSL were purified to homogeneity using a Qiagen Ni-NTA column. Purity was
assessed by SDS-PAGE gel electrophoresis (data not shown). After purification, protein
was stored in Enzyme Storage Buffer (50 mM potassium phosphate buffer, pH 7.0,
containing 150 mM KCl, 1 mM DTT, 1 mM EDTA, and 10% (v/v) glycerol) at -80°C.
Introduction of point mutations in the human ADSL plasmid was done using QuikChange
site-directed mutagenesis. The QIAspin kit was used for cDNA extraction and
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purification. DNA sequencing was performed at the CU Cancer Center DNA Sequencing
& Analysis Core to confirm mutations. Slight modifications were made to the
purification for ITC and X-ray Crystallography. Following the purification using the
Qiagen Ni-NTA column, thrombin was added to the eluted fraction and it was dialyzed
overnight at 4°C in ADSL Running Buffer (5 mM HEPES pH 7.0, 150 mM KCl, 2 mM
DTT) to cleave the His-tag. The protein was purified by size exclusion chromatography
using S200 sepharose resin and concentrated to 10 mg/mL for crystallography, and to
200-400 µM for ITC. Concentrations were measured by the absorbance at 280 nm using
an experimentally determined extinction coefficient of 0.782 L g-1cm-1 (43,150 M-1cm-1)
for thrombin cleaved ADSL and 0.770 L g-1cm-1 for His-tagged ADSL following
previously established procedures (Gill and von Hippel 1989).
Static Light Scattering
Size Exclusion Chromatography-Multi-Angle Light Scattering measurements
were performed on a Wyatt miniDAWN TREOS connected to a Shimadzu UFLC and a
Wyatt WTC-030S5 size exclusion column. Samples of 350 µg of His-tagged ADSL
diluted in Enzyme Storage buffer were run in duplicate. PBS was used as the mobile
phase and flowed at 0.5 mL/min. Calibration was checked using 2 mg/mL bovine serum
albumin. Data were analyzed with ASTRA software, and 0.185 was used as the dn/dc
value.
Enzyme Assays and Kinetic Studies
Enzyme kinetic experiments were performed on a UV-Vis Spectrophotometer
Evolution 3000 from Thermo Scientific using 1 mL quartz cuvettes at 25°C. ADSL with
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the His-tag intact was used for enzyme assays, as it has been shown that the His-tag does
not affect ADSL activity for SAMP (Lee and Colman 2007). Experiments were run with
concentrations of 0.11 mg/mL and 0.19 mg/mL for WT and R303C ADSL, respectively.
Frozen samples were incubated for ~2 hours at 25°C before measurements were taken to
assure restoration of full activity (Lee and Colman 2007). SAMP enzyme assays of
ADSL were measured in triplicate at 25°C in 40 mM Tris-HCl (pH 7.4) with varying
concentrations of SAMP (1 - 60 µM). Specific activity was measured from the decrease
in absorbance of SAMP at 282 nm as it was converted to AMP and fumarate. The assay
was monitored over 30 seconds in a 1 mL volume. The difference in extinction
coefficient of 10,000 M-1 cm-1 between SAMP and AMP was used to calculate the
specific activity. SAICAR enzyme assays of ADSL were measured in triplicate at 25°C
in 40 mM Tris-HCl (pH 7.4) with varying concentrations of SAICAR (1 - 100 µM).
Specific activity was measured from the decrease in absorbance of SAICAR at 269 nm as
it was converted to AICAR and fumarate. The assay was monitored over 30 seconds in a
1 mL volume. The difference in extinction coefficient of 700 M-1 cm-1 between SAICAR
and AICAR was used to calculate the specific activity. To determine the kinetic
constants, the initial velocity data were fitted to the Hill equation, υ =
Vmax*[S]n/(K0.5n+[S]n) for WT and R303C ADSL and υ = Vmax*[S]/(KM+[S]) for R303C
ADSL, using the Enzyme Kinetics Module 1.3 of Sigma Plot version 10 (SPSS Inc.). The
kcat value was calculated from Vmax and the enzyme concentration [E] via the equation kcat
= Vmax/[E].
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Isothermal Titrations Calorimetry (ITC)
ITC experiments were conducted using a NANO-ITC system (TA Instruments,
Utah, USA). Thrombin cleaved WT ADSL was dialyzed overnight against a solution of
25 mM HEPES pH 7.0, 150 mM KCl, and 2 mM DTT. AMP was brought to a
concentration of 2.5 mM using the buffer in which WT ADSL was dialyzed. ITC runs of
WT ADSL with AMP were performed in duplicate and comprised of a single 1µl
injection followed by 24, 2 µl injections for a total of 25 injections of 2.5 mM AMP into
0.250 mM WT ADSL. Each injection was spaced 250 seconds apart. ITC experiments
were performed in an identical method, injecting AICAR instead of AMP into 0.225 mM
WT ADSL. In addition, AMP and AICAR were titrated in an equal manner into 0.280
mM R303C ADSL. Data sets were analyzed with NanoAnalyze software and fit to an
independent model concurrently with a blank constant model to adjust for heat of
dilution.
Crystallization of WT and R303C ADSL
Initial crystal conditions for both WT and R303C ADSL were determined from
high-throughput screening of Qiagen Nextel screens, Classics and PEG I, in a 96 sitting
drop format using an Art Robbins Phoenix robot. The drops consisted of 0.4 µL protein
solutions and 0.4 µL precipitate in a 100 µL reservoir. Initial screening exhibited multiple
hits; however, a solution containing 0.1 M Tris pH 8.0, and 20% (w/v) PEG 6000
produced the most viable crystals for WT ADSL, and 0.1 M Tris pH 8.5 and 20% (w/v)
PEG 8000 for the ADSL mutant R303C. These crystals were then optimized using
Additive HT Screen from Hampton Research. Final WT and R303C ADSL crystals were
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obtained through vapor diffusion using a 500 µL reservoir with 4 µL drops mixed 1:1
with protein solution and, for native ADSL, a precipitant gradient of 18-28% (w/v) PEG
6000, 0.1 M Tris pH 8.0, and 12.5 mM MgCl2•6H2O, and for R303C, a precipitant
gradient of 18-28% (w/v) PEG 8000, 0.1 M Tris pH 8.5, and 12.5 mM spermine
tetrahydrochloride.
X-ray Structural Determination of ADSL Structures
All X-ray native datasets were collected using crystals mounted on nylon loops
and submerged in a 5 µL cryo solution of 26% (w/v) PEG 6000 and 0.1 M Tris pH 8.0
for WT ADSL, and 26% (w/v) PEG 8000, 0.1 M Tris pH 8.5 for R303C ADSL. In order
to preserve the crystals they were submerged and flash frozen in liquid nitrogen. Frozen
crystals were mounted under a stream of dry N2 at 100 K. A WT ADSL dataset with
resolution to 2.70 Å and ADSL mutant R303C dataset with resolution to 2.60 Å were
collected at the 21-ID-D Life Science-Collaborative Access Team beamline at the
Advanced Photon Source Synchrotron. Both datasets were collected at 0.9789 Å with a
MarMosaic300 CCD detector (Rayonix). All data was subsequently processed and scaled
using Scalepack (Winn et al. 2011) and subsequent phases were determined and refined
using Phaser (McCoy et al. 2007). Initial models for both WT and R303C ADSL were
elucidated by molecular replacement using ADSL structure 2J91 as a search model for
Phaser (McCoy et al. 2007). Both structures were refined using iterative cycles of model
building and structure refinement using WinCOOT (Emsley and Cowtan 2004) and
REFMAC (Murshudov, Vagin, and Dodson 1997), respectively. Water molecules were
added to 2Fo-Fc density peaks that were greater than 1σ using the “Find Water”
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WinCOOT program function. The final model was checked for structural quality using
the CCP4 suite programs: Procheck and Sfcheck. Data processing and refinement
statistics are shown in Table 2.

Table 2: Data Collection and Refinement Statistics ADSL
WT APO
R303C ADSL
Data Collection
Space Group

P 2 12 12 1

P 2 12 12 1

85.9, 105.1, 215.0

85.8, 105.6, 217.2

90.0, 90.0, 90.0

90.0, 90.0, 90.0

50.0-2.70

50.0-2.60

No. Reflections Observed

241,786

263,513

No. Unique Reflections

48,725

58,820

Rmerge (%)

10.3 (63.1)*

12.4 (35.0)*

I/σI

14.2 (4.3)*

18.9 (4.8)*

% Completeness

89.6 (90.2)*

95.4 (97.1)*

50.0-2.70

50.0-2.60

No. Reflections in Working Set

45,972

55,609

No. Reflections in Test Set

2,450

2,979

Rwork (%)

24.3

23.0

29.2

29.8

Unit Cell Dimensions
a, b, c (Å)
α=β=γ (degrees)
Resolution (Å)

Refinement
Resolution Range

Rfree (%)
2

Mean B-factor (Å )

27.5

55.1

2

Protein B-factor (Å )

27.6

54.9

Water B-factor (Å 2 )

19.2

50.1

Bond Lengths (Å)

0.01

0.01

Bond Angles (degrees)

0.9

1.01

14,605/214

14,764/144

4

4

RMS deviation:

Protein / Water Atoms
Monomers in Asymmetric Unit

* The last resolution shell is shown in parentheses.
a Rmerge=ΣhΣi|Ii(h)−〈I(h)〉|/ΣhΣiIi(h), where Ii(h) is the ith measurement
and 〈I(h)〉 is the weighted mean of all measurements of I(h).
b Rwork and Rfree=h(|F(h)o|−|F(h)c|)/h|F(h)o| for reflections in the
working and test sets.
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Modeling of AMP/AICAR and Fumarate Binding in the Active Site
Apo structures of WT ADSL with either AICAR or AMP were neutralized with
the TLEAP module from the Amber10 simulation package (Pearlman et al. 1995, Case et
al. 2005) and solvated using TIP3P water molecules (Jorgensen et al. 1983). The final
system was then energy minimized using the Amber 10 simulation package to obtain the
final structure. Initially, each system’s protein was restrained, and the solvent was
minimized for 5,000 steps to remove any unfavorable contacts that occurred within the
water. Then, each system (solvent and molecule) was allowed to energy minimize for
20,000 steps, starting with 10,000 steps of steepest descent and switching to 10,000 more
steps of conjugate gradient minimization. The force field used was ff99SB (Hornak et al.
2006). We removed residues outside of 30 Å from AMP/AICAR active site. This was
done to reduce computational demand by ignoring distant parts of the protein not relevant
for the present problem. However, 30 Å was long enough to focus on a sufficiently large
region around the active site to avoid any artifact due to small system size. All the
calculations were performed at University of Denver’s High Performance Computing
facility, which is a Linux cluster with 22 twin nodes, each node having eight cores.
Results
WT and R303C ADSL Enzyme Kinetics
To ensure that the previously observed reduction in activity of the ADSL
possessing the R303C mutation was not due to aberrant tetramer formation or outright
global instability of the mutated protein in solution, static light scattering was employed
to determine the polymeric distribution of the R303C and WT ADSL. As expected, WT
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ADSL is predominantly found to be a tetramer, 92.7 ± 2.6%, with aggregates
contributing the final percentage. Similarly, R303C ADSL is predominantly a tetramer,
94.3 ± 0.1%, with aggregates contributing the final percentage. Observed weights of the
WT and R303C ADSL tetramers were 225.0 ± 2.9 kDa and 214.5 ± 12.2 kDa, which is in
close agreement with the His-tagged WT and R303C ADSL predicted tetrameric weights
of 228.4 and 228.1 kDa, respectively, suggesting that the R303C mutation results in no
degradation of the ADSL tetramer.
Previously, a report noted that the ADSL carrying the R303C mutation displayed
nonparallel decrease in activity at a single concentration (Zikánová et al. 2010).
Additionally, the kinetic parameters for human ADSL utilization of SAICAR have never
been fully determined. Interestingly, Stone, Zalkin, and Dixon (1993) detail a KM and kcat
of ADSL for SAICAR. Unfortunately, the boundaries of ADSL were not well established
at the time of that study, resulting in their use of a 25 amino acid N-truncated version of
ADSL and not accounting for cooperativity. Unfortunately, a subsequent study by
Kmoch et al. (2000) also did not account for ADSL cooperativity, nor did they report on
the R303C mutant. This has left ambiguity to the kinetic parameters surrounding ADSL
ability to use SAICAR as a substrate. To further investigate the R303C phenomenon and
determine the KM and kcat of ADSL for SAICAR, kinetic assays were performed on both
WT and R303C ADSL using SAICAR and SAMP as substrates (Zikánová et al. 2010).
Both WT and R303C ADSL had measurable activity that could be evaluated by
monitoring the UV absorbance of either SAMP or SAICAR. As WT ADSL was
previously reported not to follow simple Michaelis-Menten kinetics for SAMP and
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perhaps be cooperative, the Hill equation was initially employed for calculating WT
ADSL’s kinetic parameters (Table 3) (Ariyananda et al. 2009). The resulting Hill
coefficients of WT ADSL for SAMP and SAICAR are both significantly above one,
indicating cooperativity for the substrates. The resulting kcat and K0.5 of WT ADSL for
SAMP was in agreement with a prior study that utilized the non-truncated form of ADSL
(Ariyananda et al. 2009). For WT ADSL’s utilization of SAICAR, its K0.5 was 1.8 ± 0.1
µM, which is only slightly higher than SAMP’s. However, WT ADSL’s kcat for SAICAR
was 1.6 fold higher than that for SAMP suggesting that ADSL is more kinetically
efficient for the catalysis of SAICAR over SAMP. This is confirmed by WT ADSL’s
kcat/K0.5 for SAICAR being 2 fold higher than SAMP’s. Additionally, the kcat for both
substrates was found not to be diffusion limited.
Table 3: Enzymatic Activities of ADSL with SAMP and SAICAR at 25 C
SAMP
SAICAR
WT

R303C

WT

R303C

52.2 ± 1.8

2.33 ± 0.07

90.2 ± 1.9

27.8 ± 0.8

kcat,H (%)

100 ± 3

4.5 ± 0.1

100 ± 2

31 ± 1

K0.5 (µM)
Hill Coeff

2.1 ± 0.2
1.5 ± 0.2

2.3 ± 0.12
1.03 ± 0.08

1.8 ± 0.1
1.22 ± 0.09

8.4 ± 0.8
0.94 ± 0.06

kcat,H/K0.5 (sec-1µM-1)

25.0

0.99

49.6

3.37

kcat,M (1/sec)

N/A

2.36 ± 0.04

N/A

27.2 ± 0.4

kcat,M (%)

N/A

4.5 ± 0.1

N/A

30 ± 1

KM (µM)

N/A

2.4 ± 0.2

N/A

7.8 ± 0.4

kcat,M/KM (sec-1µM-1)

N/A

0.99

N/A

3.45

kcat,H (1/sec)

The kcat, K0.5, KM, and Hill coefficient were determined by varying substrate concentration and fitting
data to the Hill Equation (H) or the Michaelis-Menten Equation (M) in Sigma Plot. Protein was
reconstituted for 2 hours at 25 oC prior to measurements. R303C activity is relative to % WT. The
values are shown along with their standard errors. N/A stands for not applicable.
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Introduction of the R303C mutation into ADSL has multiple effects. Initially
expecting similar cooperativity observed in WT ADSL, the Hill equation was utilized
(Table 3). Unlike WT ADSL, the R303C ADSL demonstrates no cooperativity, with a
Hill coefficient for both substrates of one. As a result, the simple Michaelis-Menten
equation was employed for R303C. The R303C ADSL mutation reduces kcat to 4.5% and
30% of that relative to WT ADSL for SAMP and SAICAR, respectively. Interestingly,
this 7-fold difference in residual in vitro activity is in line with cell free extract studies of
a Type II patient’s fibroblasts carrying the R303C mutation, which had 3% of normal
SAMP activity and 30% of normal SAICAR activity (Race et al. 2000, Van den Bergh,
Vincent, Jaeken, and Van den Berghe 1993). As a result, the ratio of activity of WT
ADSL for SAICAR:SAMP is 1.7, which is in agreement with a previously published
ratio of 1.6, but the ratio of activity for the R303C mutant ADSL shifts to 11.5
(Ariyananda et al. 2011). Interestingly, KM values of R303C ADSL increased for
SAICAR compared to that of WT ADSL. The change observed in KM of R303C ADSL
for SAMP is almost negligible, with the KM for SAICAR increasing more than 4-fold.
This may initially suggest the mutation affects the ability of R303C ADSL to bind
SAICAR more than SAMP resulting in the disparity in their cleavage. However, the rate
of SAICAR cleavage by R303C ADSL is 5 times more rapid than that for SAMP at
R303C ADSL’s SAMP KM. Therefore, the effect of the R303C mutation on ADSL may
not solely be reflective in its divergent ability to bind SAICAR and SAMP. It suggests
that R303C may affect the catalytic mechanism of SAMP and SAICAR in addition to
binding of the substrates.
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Isothermal Titration Calorimetry (ITC)
To explore the possible thermodynamic factors involved in the non-parallel
reduction in activity resulting from the R303C mutation and in general ADSL-substrate
interactions, ITC was performed on WT and R303C ADSL with their products AMP and
AICAR. By measuring the amount of heat liberated per injection as a function of the
molar ratio of the substrate and protein, thermodynamic parameters for R303C and WT
ADSL’s interaction with their products were calculated (Table 4). Intriguingly, product
binding does not show any evidence of cooperativity, as the data fit to an independent
model rather than a multiple binding site model. This does not necessarily rule out the
possibility that the substrate binding is cooperative, but suggests that cooperativity may
require inclusion of interactions between the fumarate component of the substrates and
ADSL, which is lacking in the products.
Table 4: ITC Thermodynamic Parameters of ADSL
AMP
AICAR
WT
R303C
WT
R303C
Kd (µM)
54 ± 3
130 ± 8
34 ± 2
121.9 ± 0.9
-1
ΔH (kJ*mol )
-35 ± 2
-5.9 ± 0.2
-53 ± 1
-16.7 ± 0.5
-1
TΔS (kJ*mol )
-12 ± 1
15.92 ± 0.06
-28 ± 1
5.3 ± 0.5
-1
ΔG (kJ*mol )
-23.9 ± 0.1
-21.8 ± 0.2
-25.1 ± 0.1
-21.95 ± 0.02
n
0.99 ± 0.01
1.01 ± 0.04
1.00 ± 0.02
1.00 ± 0.02
Data sets were collected in duplicate and analyzed with NanoAnalyze software and fit to an
independent model concurrently with a blank constant model to adjust for heat of dilution. All
measurements were from 25 injections of 2.5 mM AMP into 170 µL protein in 25 mM HEPES, pH
7.0, 150 mM KCl, 2 mM DTT at 20°C.

Beyond the absence of cooperativity observed, the Kd values for WT ADSL were
54 and 34 µM for AMP and AICAR, respectively (Table 3). The thermodynamic
properties that are responsible for AICAR and AMP binding to WT ADSL globally are
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similar with the enthalpic component, ΔH, being the predominant driving force and the
entropic component, ΔS, being unfavorable. Although similar, the thermodynamic
properties are not identical. AICAR binding liberates an additional 18 kJ/mol, suggesting
an additional hydrogen bond may be formed between AICAR and WT ADSL that is
absent in an AMP and WT ADSL complex. The lack of this additional enthalpic
contribution is partially offset in the AMP and WT ADSL complex by the reduced
unfavorable entropic component compared to the AICAR and WT ADSL complex.
Overall, this leads to a difference in ΔG of AMP and AICAR to WT ADSL to be only 1.2
kJ/mol in AICAR’s favor.
Intriguingly, the R303C mutation impacts the ability of ADSL to form a complex
with AMP and AICAR in two distinct manners. The enthalpic component for both
products decreases by a similar degree of ~30 kJ/mol suggesting the loss of one to two
hydrogen bonds, whose identity could be common between the two products and ADSL.
Additionally, the R303C mutation shifts the ADSL complex formation with AMP and
AICAR from an unfavorable to favorable entropic event. Taken together, these
thermodynamic factors result in a similar decrease of ΔG and increases of 76 and 88 µM
in the Kd of AMP and AICAR respectively. As a result, the R303C mutation appears to
negatively affect ADSL’s interaction with AMP and AICAR almost indistinguishably.
X-ray Structural Elucidation of R303C and WT ADSL
Recently, a study proposed that the R303C mutation may distort the active site
cleft (Zikánová et al. 2010). To investigate the structural effects of the R303C mutation
on ADSL and how these effects might be linked to the lower activity and unique
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specificity of ADSL with the R303C mutation, the crystal structure of R303C ADSL
(R303C-ADSL) was elucidated to 2.60 Å. A homo-tetramer in the asymmetrical unit was
observed, with each monomer composed of 16 α -helices and 3 small β -sheets, which
can be further divided into three domains (Fig. 12, 13). Electron density was observed for
the majority of all 5–476 ADSL residues in all monomers, with residues 5–112 forming
domain 1, residues 113–364 as domain 2, and 364–476 as domain 3. A notable exception
was the residue range 286–291 in all monomers. These residues comprise the β3-α10
loop, also known as the C3 loop, which is located near ADSL’s active site and expected
to contain an important catalytic serine, S289. The lack of density for this region is not
fully unexpected, as it has been unobserved in all but one bacterial ADSL X-ray
structure. As a result, the loop is suggested to be highly flexible. Apart from the expected
differences in the positions of the residues just prior to and after the missing density of
the β3-α10 loop, the only other notable difference observed between the four monomers
of R303C-ADSL resides in domain 3 of the structure. This domain is on the periphery of
the tetrameric complex likely resulting in the small alterations and higher B-factors
between the four monomers in that region (Fig. 13).
Despite these differences on the periphery of the protein, from a distance the
R303C-ADSL globally resembles that of the PDB entry 2VD6 ADSL with its four active
sites a mixture of active site bound SAMP, or AMP with fumarate (ADSL-SAMP) as
well as AMP bound ADSL PDB entry 2J91 (ADSL-AMP). Unlike ADSL-AMP where
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Figure 12: Sequence alignment of ADSL from various species. ADSLs are from H. sapiens
(GenBank AAC83935.1), M. musculus (GenBank AAB60684.1), B. subtilis (NCBI Reference
Sequence: YP_003865018.1), and C. griseus (NCBI Reference Sequence: NP_001230974.1).
Secondary structure of hADSL according to Defined Secondary Structure of Proteins (DSSP) is
represented by green cylinders (helical regions), orange arrows (β-sheet regions), black lines (loops),
and black dashes (unstructured regions). Mutation site 303 is marked with an asterisk. The location of
helices α3 and α4 is highlighted with a red box. The C3 loop is enclosed in black brackets. Catalytic
residues H159 and S289 are marked with blue asterisks. Domains 1, 2, and 3 are indicated with bars in
shades of brown.

all of the active sites are indistinguishably bound to AMP, ADSL-SAMP has its active
sites 1 and 2 filled with AMP and fumarate, while the SAMP was observed in active sites
2 and 4 (Fig 14a,b). Both of these ligand bound structures previously have alluded to
ADSL active sites being formed by three contributing monomers. For example, in the
active site 1, the monophosphate group of AMP hydrogen bonds to three residues from
chain A. The fumarate interacts with 3 residues from chain A bridging across to
interactions with two residues from chain B, and one from chain D (Fig. 14a).
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Figure 13: Side and Top view of WT homo-tetramer. P212121 asymmetric unit of WT crystal.
Monomers A, B, C and D are rendered red, green, blue, and yellow, respectively. Domains 1-3 are
indicated for Monomer C. Active sites are indicated with arrows.

The ADSL-SAMP active sites with SAMP bound have similar intermonomeric
interactions (Fig. 14b). Not surprisingly, upon inspection of the corresponding active site
of R303C ADSL, density for the R303 side chain is largely absent with only enough
remaining to represent a mutation to cysteine at that position (Fig. 14c). Based on the
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ligand bound structures, this mutation would appear to simply eliminate the hydrogen
bonds formed between the monophosphate in the AMP, or SAMP, and ADSL. This loss
of the phosphate-R303 interaction, which also likely exists with AICAR, could be
reflected in the enthalpy change detected by ITC for AMP and AICAR. However, upon
closer examination by superimposing the active sites of R303C-ADSL with the
corresponding sites in ADSL-SAMP revealed that the two structures’ corresponding
active sites are not entirely identical, giving possible credence to an earlier study’s
suggestion that the R303C mutation may disrupt the active site cleft (Zikánová et al.
2010). Specifically, comparison of R303C-ADSL’s active sites with ADSL-SAMP’s
corresponding fumarate and AMP bound active sites shows a 2.5 Å shift of α-helices 2, 3
and 4 (Fig. 15a). This shift is also observed between R303-ADSL and ADSL-AMP.
Interestingly similar, but not exact, shifts are also observed between R303C-ADSL’s
active sites and the SAMP filled active sites of ADSL-SAMP. To determine if the shift in
α-helices 2 – 4 was related to the R303C mutation or a conformational change related to
substrate binding, the structure of WT ADSL in its apo form (WT-ADSL-apo) was
elucidated to 2.70 Å (Fig. 15b). Similar to the ADSL-R303C and ADSL-SAMP, electron
density for residues 283–293 (β3-α10 loop) was not observed. Similarly to R303CADSL, WT-ADSL’s monomers were largely indistinguishable outside of the domain 3.
Intriguingly, comparison of the WT-ADSL-apo with ADSL-SAMP revealed a 2.7 Å shift
of α-helices 2 – 4 in line to those observed previously in the R303C-ADSL and ADSLSAMP comparison, indicating that substrate binding is likely the major cause of the shifts
observed between the ADSL-R303C and the ADSL-SAMP (Fig. 15c), while comparison
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Figure 14: Comparison of ADSL active sites for WT, WT with substrate, and R303C mutant. (a)
Wall-eyed stereo view of an ADSL-SAMP active site with AMP and fumarate occupying the active
site. AMP is rendered pink and fumarate is rendered tan. Heteroatoms are colored according to their
element. Water molecules (grey) are depicted as spheres and are scaled to 50% for clarity. The
monomer each residue belongs to is given in parentheses after the residue number. (b) Wall-eyed stereo
view of an ADSL-SAMP active site with SAMP occupying the active site. SAMP is rendered purple,
and heteroatoms and water molecules are as in (a). (c) Wall-eyed stereo view of R303C ADSL active
site. Monomers A, B and D are rendered red, green, and yellow, respectively. Heteroatoms are colored
according to their element. Water molecules (cyan) are depicted as spheres and are scaled to 50%, and
the side chain of R85 is hidden for clarity.
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Figure 15: Substrate induced α -helices 2, 3 and 4 shift. (a) Wall eyed stereo view comparing the
mobile loop α2-α4 between ADSL-SAMP (grey) and R303C-ADSL. (b) Wall-eyed stereo view of WT
active site colored salmon, light yellow and pale green, with waters colored aqua. Heteroatoms are
colored according to their element. Water molecules are depicted as spheres and are scaled to 50%, and
the side chain of R85 is hidden for clarity. The monomer each residue belongs to is given in parentheses
after the residue number. (c) Wall eyed stereo view comparing the mobile loop α2-α4 between ADSLSAMP and WT ADSL. Coloring is as in (a) and (b). (d) Wall eyed stereo view comparing the mobile
loop α2-α4 between R303C and WT ADSL. Coloring is as in (a) and (c).
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of WTADSL-apo to R303C-ADSL revealed nearly identical structures (Fig. 15d). In
addition, WTADSL-apo reveals an additional apo form of the ADSL active site that is
divergent from product and substrate bound active sites previously observed.
Modeling of AMP/AICAR and Fumarate Binding in the Active Site
Currently, no crystal structure for WT ADSL with AICAR bound has been
resolved. Utilizing the elucidated WT-ADSL-apo and ADSL-SAMP structures along
with the understanding of local active site shifts within the active site upon substrate
binding; AICAR and fumarate were modeled into the active site. Specifically, the AMP
and fumarate bound active site of 2VD6 was employed as a template for the initial
location of AICAR and fumarate within an active site of the WT-ADSL-apo. Using the
Amber10 simulation package, by energy minimization the ADSL-AICAR-fumarate
model structure was determined (Fig. 16a). To validate the modeling parameters used, we
also energy minimized the structure with AMP and fumarate instead in the WT-ADSLapo active site. The resulting AMP and fumarate bound ADSL model was nearly
identical to that of AMP and fumarate bound in ADSL-SAMP.
As is evident from the figure, the placement of the fumarate, phosphate and ribose
groups of AICAR and SAMP within the ADSL active site is similar (Fig. 16b). However,
the remaining structure of the two substrates forms divergent interactions within the
active site. This divergence could be a result of a rotatable bond between AICAR’s
imidazole ring and carbonyl carbon, whereas the presence of the pyrimidine in AMP
eliminates the ability of the corresponding bond to rotate (Toth and Yeates 2000). As a
result, this flexibility in AICAR and an amine group substituent of its imidazole ring
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Figure 16: ADSL-AICAR-fumarate model. (a) Wall-eyed stereo view of model of WT active site
with AICAR and fumarate occupying the active site. AICAR and fumarate are rendered yellow.
Heteroatoms are colored according to their element. The monomer to which each residue belongs is
given in parentheses after the residue number. (b) View of model of WT active site with AMP and
fumarate overlaying model of WT active site with AICAR and fumarate. WT with AMP is rendered
grey with AMP in pink and fumarate in tan, while WT with AICAR residues are teal with AICAR and
fumarate in yellow.

potentially allows the amine to stick out in a space previously occupied by a water
molecule potentially facilitating hydrogen bond with the hydroxyl group of the conserved
S334 (Fig 12). Additionally, the rotation of the AICAR amide causes an alteration in the
R329 side chain to form a hydrogen bond with AICAR’s amide group.
Discussion
Origins of ADSL Cooperativity
The elucidation of the ADSL-SAMP structure has previously been suggested to
support cooperativity in human ADSL, as AMP and fumarate are found in two active
sites and with the other two occupied by SAMP. However, previously limited
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biochemical data existed to support the origins or form of the cooperativity found in
ADSL. Interestingly, the kinetic and thermodynamic properties of the WT ADSL and the
R303C mutant suggest that the involvement of all three monomers that comprise an
ADSL active site is necessary to achieve ADSL’s positive cooperativity. Specifically, no
cooperativity was observed when binding AICAR, or AMP, to WT ADSL. Binding of
these products form the majority of their interactions with only two of the monomers. For
example, in active site 1, AMP interacts with six residues from monomer A, and one
from monomer B. Additionally, the phosphate group of AMP is anchored with two
additional residues from a relatively immobile portion of monomer D. (Fig. 14a). This
leaves the fumarate product to span interactions between monomer A’s mobile α-helices
2 – 4, monomer B, and the near β3-α10 catalytic loop region of monomer D, suggesting
that it is necessary for cooperativity to be observed. In line with this hypothesis, mutation
of R303 to cysteine, which removes two hydrogen bonds, thus removing the majority of
the interactions between monomer D and SAMP, results in no cooperativity (Fig. 14b).
Beyond the necessity for the substrate, or products, to involve all three monomers
when binding to achieve an allosteric response, comparison of the WT-ADSL-apo and
ADSL-SAMP active sites provided a glimpse into the model of allosteric regulation that
ADSL undergoes. Specifically, the WT-ADSL-apo active sites are considerably more
open to the bulk solvent then those of the ADSL-SAMP and ADSL-AMP structures (Fig.
17a). The 2.7 Å shift of α-helices 2, 3 and 4 observed between the WT-ADSL-apo active
sites and those bound with AMP, or AMP and fumarate, illustrates a clamping down of
the active site over SAMP, or AMP. With AICAR and SAICAR having homologous
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phosphate, fumarate, and ribose moieties to that of AMP, the same shift is likely to occur
upon the binding of these ligands as well. This closure of the active site around SAMP
suggests that a concerted model of allosteric regulation would not be possible (Fig. 17c).
In other words, if this shift occurred in a neighboring active site as a result of binding
SAMP and SAICAR for the reaction running in the forward direction, SAMP attempting
to bind to the neighboring active site would be sterically impeded. This would not be
reflective of the positive cooperativity observed. Applying sequential allosteric regulation
to the reverse reaction is less certain. The binding of AMP and AICAR would also be
sterically impeded from binding to an active site that already underwent a shift of αhelices 2, 3 and 4. However, as illustrated by the thermodynamic information, the binding
of AMP and AICAR is does not illustrate cooperativity. With fumarate binding at the top
of the active site, which is exposed to the bulk solvent, a concerted model cannot be ruled
out in the reverse direction (Fig. 16b).
Beyond the sequential model of allosteric modulation of ADSL, in what order, or
the extent to which the active sites fill with substrates remains an open question. The
ADSL-SAMP structure has its two active sites on the same end of ADSL occupied by
SAMP and other distal active sites bound with fumarate and AMP. The absence of
SAMP in all of the active sites could be due to restraints of the enzyme imposed by the
crystal lattice, but alternatively might propose that substrates bind to adjacent active sites
first, or only can bind to them. The latter would infer that the active sites at one end of the
ADSL tetramer communicate to its distal neighbors. Although the mild loss of
cooperativity observed by Ariyananda et al. (2009) by an ADSL mutation L311V at the
66

center of the tetramer would support this possibility, additional structurally guided
mutagenesis along monomer interfaces and molecular dynamics simulations will be
required to completely tease out the global allosteric nature of ADSL.

Figure 17: Constriction of the ADSL active site upon substrate binding. (a) Surface rendering of
WT-ADSL-apo active site 1. WT active site depicted in salmon, light yellow and pale green
corresponding to monomer A, B, and D respectively. R85 side chain is shown with transparency to
reflect the lack of electron density for the side chain in all monomers. AMP and fumarate from active
site 1 of ADSL-SAMP was placed in the apo active site for scaling purposes. (b) Surface rendering of
SAMP and fumarate bound active site 1 of ADSL-SAMP. Coloring of light grey, medium grey, and
dark grey correspond to monomers A, B, and D respectively. (c) Surface rendering of SAMP and
fumarate bound active site of ADSL-SAMP. Coloring of light grey, medium grey, and dark grey
correspond to monomers A, D, and C respectively. All waters were removed from surface renderings
in (a-c).

Catalytic Effects of R303C Mutation
The loss of cooperativity because of the R303C mutation removal of hydrogen
bonds with one of the three monomers comprising the active site as reflected in the
structures of ADSL-SAMP, or ADSL-AMP, would not itself explain the divergent
catalytic properties of ADSL observed towards SAICAR and SAMP. However, the
combination of the kinetic and thermodynamic data coupled with the structural evidence
suggests that the R303C mutation illuminates SAICAR as a better substrate for ADSL. At
first glance, the unparallel reduction in kcat between SAMP and SAICAR upon the R303C
mutation could suggest that the divergence in catalytic ability of ADSL between SAMP
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and SAICAR is due to a lack of substrate binding that favors SAICAR, or AICAR
binding over that of SAMP. However, the KM for SAICAR is slightly elevated relative to
that of SAMP indicating that binding of SAICAR might be slightly weaker (Table 3).
Moreover, the ADSL ligand bound structures have R303 forming hydrogen bonds to the
phosphate group that is conserved between SAICAR and AICAR (Fig. 14). Also, the
thermodynamic data reflects that the mutation causes a loss of enthalpy at almost equal
magnitude for both AICAR and AMP, reflective of a loss of the same ADSL-phosphate
group interactions. Despite the loss of the bond to the phosphate group, the overall ΔGbind
for both products remains similar to WT ADSL. This is accomplished by shifting the
product binding from an unfavorable to favorable entropic event. The resulting Kd’s for
both substrates are nearly equally decreased by approximately 2.5–3 fold. This near equal
drop in Kd but not kcat suggests that the R303C mutation is indirectly affecting the
catalytic ability of ADSL divergently for its two substrates. In other words, this
thermodynamic, kinetic, and structural evidence suggests that the substrate can bind to
the active site at a significant affinity despite the R303C mutation. As a result, unlike WT
ADSL, the R303C mutant is likely operating at rapid equilibrium state, where if the
substrate binds to ADSL, most substrate will dissociate, and only a small amount will be
converted to product.
This would suggest that ADSL is more efficient at cleaving the fumarateAICAR/AMP bond of SAICAR than SAMP. The inequality of catalysis might suggest
that SAICAR and SAMP do not follow the same mechanistic pathway. The reaction
mechanism for conversion of SAMP and SAICAR by ADSL has been previously
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described as a general acid-base mechanism resulting in β-elimination of fumarate (Fig.
18) (Tsai et al. 2007). Although, the conversion of SAICAR to AICAR and fumarate
could follow the same steps as the SAMP to AMP mechanism, due to the presence of an

Figure 18: Proposed mechanism for SAICAR to AICAR plus fumarate and for SAMP to AMP
plus fumarate.
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additional carbonyl in SAICAR, there is another possibility. In this SAICAR selective
pathway, the first two steps are the same: the Cβ-proton is removed, and the negative
charge is stabilized by the δ-carboxyl group. However, in the third step, as the electron
density from the double-negatively charge carboxyl group is shifted down and the Cα-N6
bond is broken, a double bond is formed between N6 and the carbonyl carbon, and
electron density is pushed up onto the carbonyl oxygen. Then, in the last step, this
negative charge moves back down to form a C-O double bond as N6 becomes protonated
by H159. This negatively charged oxygen may be stabilized by nearby positively charged
residue, R235. This additional stabilization of the intermediate may be a factor in the
faster reaction rate of SAICAR compared to SAMP.
An alternative possibility, or potential additional factor, for the inequality of bond
cleavage between SAMP and SAICAR is the ability of SAICAR to be positioned with the
active site in a more catalytically effective orientation than SAMP. The loss of the
hydrogen bonds that R303 contributed to substrate binding potentially affected the ability
to orient SAMP and SAICAR ideally for cleavage. Unlike SAMP, which possess a
pyrimidine ring, SAICAR has a single rotatable bond that has been previously suggested
to infer greater flexibility to adopt different conformations (Toth and Yeates 2000). This
also might explain the lack of unparallel reduction in catalytic ability of B. subtilis
ADSL. In that case, B. subtilis ADSL has an arginine in place of human ADSL T354 that
may provide a similar influence. Unfortunately in the Palenchar and Colman (2003) study
that looked at B. subtilis ADSL corresponding human ADSL R303C mutation (B. subtilis
ADSL N276C), only performed a double mutation to mimic the human active site
70

configuration and did not include a single mutation for the corresponding arginine at
human ADSL’s T354. This prevented observing whether elimination of anchoring
ADSL’s substrates by a third arginine resulted in unparallel catalytic ability.
Additionally, the thermodynamic data suggests that AICAR forms an additional
hydrogen bond not present in the ADSL-AMP complex. The enthalpic divergence
between the two substrates remains after the introduction of the R303C mutation. The
ability of SAICAR to possess an additional point of contact within the ADSL active site
could ensure that SAICAR properly oriented within the active site more often then
SAMP, contributing to the unparallel kcat between SAMP and SAICAR observed. Based
on the ADSL-AICAR-fumarate model, the additional hydrogen bond could be reflective
of an interaction between AICAR and the highly conserved S334 (Fig 16a). Curiously,
even in human ADSL’s distant homolog of B. subtilis, this serine is conserved. This
serine has not previously been implicated in substrate binding or catalysis, as it does not
interact directly with SAMP or AMP within the ADSL-SAMP and ADSL-AMP
structures. Naturally, additional site-directed mutagenesis efforts within the active site
including S334, or an X-ray structure of ADSL with SAICAR, or AICAR, will be
necessary to fully identify the ADSL residue acceptor that forms the additional hydrogen
bond with AICAR and bring final clarity to the unparallel catalytic activity observed.
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